Use of Simultaneous Inference Under Order Restriction, Stepdown Testing Procedure and Stage-wise Sequential Optimal Design in Clinical Dose Study by Jia, Gang
USE OF SIMULTANEOUS INFERENCE UNDER
ORDER RESTRICTION, STEPDOWN TESTING
PROCEDURE AND STAGE-WISE SEQUENTIAL
OPTIMAL DESIGN IN CLINICAL DOSE STUDY
by
Gang Jia
B.S. Management Science, Fudan University, 1991
M.A. Statistics, University of Pittsburgh, 1998
Submitted to the Graduate Faculty of
the Department of Statistics in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
University of Pittsburgh
2004
UNIVERSITY OF PITTSBURGH
DEPARTMENT OF STATISTICS
This dissertation was presented
by
Gang Jia
It was defended on
December 6th, 2004
and approved by
Leon J. Gleser, Department of Statistics
Allan R. Sampson, Department of Statistics
Henry W. Block, Department of Statistics
Harry S. Wieand, Department of Biostatistics
Dissertation Director: Leon J. Gleser, Department of Statistics
ii
USE OF SIMULTANEOUS INFERENCE UNDER ORDER RESTRICTION,
STEPDOWN TESTING PROCEDURE AND STAGE-WISE SEQUENTIAL
OPTIMAL DESIGN IN CLINICAL DOSE STUDY
Gang Jia, PhD
University of Pittsburgh, 2004
This dissertation discusses the design approaches of adaptive dose escalation study and the
analysis methods of dose study data, and the relationship between the study design approach
and data analysis methods.
A general max-min approach to construct simultaneous confidence intervals for the mono-
tone means of correlated and normally distributed random samples is proposed to analyze
correlated dose response data. The approach provides an accurate, flexible and computation-
ally easy way to obtain critical values of simultaneous confidence intervals under monotone
order restriction.
A stepdown testing procedure for analyzing dose study data is examined and a modified
stepdown testing approach is proposed to incorporate the adaptive sampling nature of the
study data. A mixture normal approximate approach of the dose response is proposed to
analyze the binary outcome with small sample size at the first stage of the adaptive design.
Finally, an optimal stage-wise adaptive clinical dose study design is proposed to be
applied in a dose escalation study with binary outcome and correlated dose response. The
iii
study design criteria is defined as a weighted average power to identify all effective dose
levels. A back-induction algorithm is used to obtain the optimal design parameters. The
values of optimal design parameters vary when different analysis methods are used to analyze
the study data.
Simulation studies are performed to illustrate the two proposed analysis methods and
the proposed optimal design approach.
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1.0 INTRODUCTION AND BACKGROUND
1.1 INTRODUCTION
Dose study is an important part in drug development. A safe and potentially effective dose
strategy needs to be identified before a full-scale phase III clinical trial can start. Especially
in areas involving severe or life threatening outcomes, due to the usually very low event rate
which in turn requires large sample size, only one or two dose groups are feasible in the final
study.
Phase II clinical trials are conducted to screen experimental drugs and select promising
candidates to be tested in Phase III confirmatory trials. Information obtained in Phase II
studies also provides critical information for the efficient design of Phase III trials. Tradi-
tionally, Phase II trials have focused on a single dose level that has been determined in Phase
I studies. MED-Minimum Effective Dose, is often used when toxicity is of primary concern,
and MTD-Maximum Tolerated Dose, is often used when the targeted disease is severe and
the risk of not being sufficiently treated is high. In modern drug development, however, it
is increasingly common for potential therapies to enter into Phase II testing where the best
choice of dose level is less clear. This is often the case in modern cancer therapeutics and
cardiovascular medicines, where many new agents under development work in biologically
complex ways and might not have a steep dose-response relationship.
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1.2 BACKGROUND
The proposed research has been motivated by a multi-center Phase II clinical trial that was
coordinated in the Cleveland Clinic Foundation Heart Center. I participated in the trial as
a project statistician. The trial was conducted to assess the effect of a new cardiovascular
drug to reduce the risk of procedure-related restenosis and subsequent adverse cardiac events.
A brief background of the experimental drug and its targeted disease are described in the
following paragraph from the study protocol:
Restenosis is a gradual loss of vessel lumen diameter resulting from thrombogenic and
wound healing processes at the site of vessel wall injury following endovascular interven-
tions and graft surgery. Restenosis is the predominant cause of failure following PTCA and
hemodialysis shunt insertions, occurring at rates of 30% and 50% respectively. Morbidity
and secondary interventions due to restenosis following PTCA (Percutaneous Transluminal
Coronary Angioplasty / Stent) is estimated to cost 2,500 lives and 2.5 billion dollars per
year in the U.S. No medical therapy is available for effective prevention of restenosis. Hep-
arin is the commonly used drug in patients undergoing PTCA or other invasive vascular
procedures. While heparin reduces the risk of acute thrombosis, it has no beneficial effect
on restenosis. TTD, a new cardiovascular medicine, was being developed to provide safe
medical prevention of immediate thrombus formation and restenosis. TTD exerts its ben-
eficial effect by diminishing the triggering of coagulation and is therefore expected to be
more efficient than other anti-thrombotic drugs in preventing the generation of thrombin
and recruitment of platelets.
The objective of this trial was to compare the efficacy of 6 different dosing strategies of
TTD with heparin in patients undergoing elective or urgent PTCA with respect to treating
the incidence of death, Myocardial Infarction and/or urgent revascularization of the target
coronary vessel within the index hospitalization or 7 days following the index PTCA. The
safety of different doses of TTD in patients undergoing elective or urgent PTCA was also
assessed with respect to the incidence of major and minor bleeding, death and hemorrhagic
stroke. The result of the Phase II trial was used to assess whether there exists a potentially
superior effect of the new drug indicating that a Phase III confirmatory trial should be con-
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ducted to verify that it can be marketed as an alternative treatment. The logical endpoint
in a cardiovascular medicine study is usually mortality, or a composite endpoint of recurrent
Myocardial Infarction, urgent target vessel revascularization and/or mortality. An alterna-
tive endpoint that can be used is the treatment success of the cardiovascular drug used with
the PTCA procedure, which can be defined as the significant reduction of lumen stenosis.
Recent development of the IVUS technique, an approach that utilizes ultrasound to measure
the lumen wall and vessel volume, make it possible to precisely measure the actual thickness
of harmful plaque inside the coronary vessel. The significant reduction of the stenosis is an
important indicator of the long term success of the treatment.
Due to the severe nature of the disease, the new drug had to be administrated in con-
junction with a partial dose of heparin. On the other hand, the potential side effects of
the new drug are also very serious, including major bleeding, disabling stroke and deadly
intracranial hemorrhage. Hence it was decided by the medical staff that a conservative dose
escalation approach would be used. The study would start from the lowest dose level. The
results of the lower dose groups would be analyzed before escalating to the next higher dose.
By escalating the dose level of the new drug, one hopes to see an increasing drug effect
in treating the target cardiovascular disease. The dose escalation continues until all of the
planned dose levels are studied, or unacceptable increased risk of the adverse events is ob-
served. Zero-dose placebo is not ethically acceptable here, so an active control arm with
full-dose heparin is used for comparison. It is assumed that the effect size increases as the
dose of new drug increases, and so does the risk of adverse events. Thus it is natural and
efficient to incorporate the directional assumption in the statistical design and analysis of
the study. Because the level of maximum tolerance has been studied in the Phase I study,
stopping the dose escalation due to safety concerns is not expected to happen and the study
will most likely to go through all the planned dose levels. Therefore, adjustment for overall
3
Type I error for safety monitoring won’t be necessary.
1.3 RESEARCH OUTLINE
The thesis can be outlined as two major parts: the adaptive experiment design, and the
analysis of the dose study data. At the experiment design stage, we propose an adaptive
design at each dose level to improve the efficiency of subject allocation. Starting from the
lowest dose level, the data will be analyzed after part of the planned number of subjects are
enrolled at the dose level. If the efficacious effect is not obvious enough, we will move to
the next higher dose level without enrolling the rest of the subjects and will subsequently
assign saved subjects to the remaining higher dose levels. By doing that, we will have more
power to analyze the drug effect if it only exists at higher dose levels, and can have a better
estimate of the effect size. On the other hand, although the study drug is presumably
more effective at high dose levels, we still need to have enough subjects at lower levels to
study its possible adverse effects, and to detect its potential effect at lower levels. Indeed,
estimating the effective dose range is also an important part of the study objective. A wider
effective dose range means that the drug can be used in broader patient population. After the
study enrollment is finished and follow up data collected, we propose to use the approaches
of simultaneous confidence intervals and stepdown testing procedure to analyze the study
data.
Topics on sequential adaptive design have been researched extensively, especially in the
area of clinical trials. However, in the area of clinical dose studies that have multiple dose
groups with monotone increasing / decreasing drug response, there has not been adequate
research on sequential adaptive design to improve study designs using the order restriction
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information. It is often assumed that the conventional hypothesis testing and/or confidence
region approaches will be used at the end of the study. As the first objective of the thesis,
I propose an optimal adaptive study design that is tailored based on the analysis approach
to be used to analyze the study data. A flexible study design criteria is defined using the
weighted expected proportion of identified effective dose levels.
At the data analysis stage, single-step or stepwise multiple testing procedures will be ex-
plored to compare the control group and each of the dose levels. The parametric regression
strategy would be normally considered to analyze the dose-response relationship. However,
the most important objection to such an approach is that we are usually interested in esti-
mations at the extreme dose range, where the choice of the form of regression model is much
more critical. Moreover, the experiment itself, rarely consisting of more than 6-7 dose levels
in a Phase II study, will provide insufficient evidence for determining the correct regression
model.
We need to perform the data analysis to find those dose levels which are effective and to
estimate their effect sizes relative to the control; such information will be important in making
the decision whether to conduct the Phase III trial and will also provide crucial information
for the design of Phase III trial. A stepdown testing procedure (Chapter 3) is a powerful
approach to identify the effective levels, as the type I error probability of each individual test
doesn’t need to be penalized to ensure that the overall family-wise type I error probability
is controlled. On the other hand, the approach of simultaneous confidence intervals has
the advantage over stepdown testing procedures in that it provides interval estimates of the
effect size, and can be used to verify a hypothesized parametric dose response relationship.
Simultaneous confidence intervals are usually overly conservative. As the second part of
this thesis, ways to improve the simultaneous confidence intervals, such as only looking at
effective dose levels and incorporating the assumption of monotone effective sizes into the
5
construction of the confidence intervals, will be studied. The third part of the thesis will
be to explore the stepwise testing procedures when the data is from studies with sequential
adaptive designs.
The data to be collected in this study is dichotomous, recorded as treatment success or
whether an endpoint event occurred. The therapeutic effect of the new drug relative to the
active controlled arm in such cases is usually measured using odds ratio, relative risk, or
difference of event rates. A problem arises at the early stages of the trial when the number
of subjects enrolled in the controlled arm is low, and the number of events that occurs is not
big enough for any asymptotic-theory-based inference to be used. Thus, it will be necessary
to explore and evaluate the performance of various normal based approaches when they are
applied in binomial settings. We will address this practical issue in each of three parts of
the thesis.
Because our proposed adaptive design involves the analysis approaches that are used to
analyze the study data, we organize the thesis in the following order: Chapter 2 discusses
simultaneous confidence intervals for correlated drug effect estimates under order restric-
tion, Chapter 3 discusses stepdown testing procedures for ordered dose effect with adaptive
sampling data, and Chapter 4 discusses a stage-wise sequential adaptive design in Phase II
clinical dose studies. The last chapter discusses my plans for future research in the three
areas studies in this thesis.
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2.0 SIMULTANEOUS CONFIDENCE INTERVALS OF MONOTONE DOSE
RESPONSE
2.1 INTRODUCTION
In a clinical dose study, it is often of interest to have confidence bands for dose-response
curves. These confidence bands can be used to form simultaneous confidence intervals for
drug response at multiple doses, or to form a confidence interval for doses yielding a given
drug response. If a parametric family of dose-response relationships can be assumed, the
parameters and the curve can be estimated using a regression approach, and the simultaneous
confidence intervals can be obtained based on the estimates of these parameters. However,
in studies of new drug development, more often than not such a parametric assumption is
not available, except that one can reasonably assume that the underlying dose response is
non-increasing or non-decreasing depending on the nature of the drug effect.
A natural estimator of the dose response under such an isotonic assumption is the isotonic
regression, which is the conventional least squares estimate of the dose response curve under
the isotonic restriction. The approach of simultaneous confidence intervals we will study in
this chapter is based on the same idea of isotonic regression, aimed to utilize the assumption
of isotonic dose response to achieve accurate and efficient interval estimates.
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2.2 PROBLEM AND MATHEMATIC MODEL
In a Phase II clinical dose study, drug response data yi1, yi2, . . . , yini have been collected at
dose levels di, i = 0, 1, 2, . . . , k. Dose level d0 represents the control arm, which can be a
zero-dose placebo group or an active control group treated with a different drug. The yij
are assumed to be normally distributed with mean µi and variance σ
2
i . Although in most
occasions, the variance is not known, we will assume that it is known here, and the extension
of our approach to the cases with unknown variance is straightforward. We assume that the
mean drug responses at dose levels d1, d2, . . . , dk are non-increasing: µ1 > µ2 > . . . > µk.
Notice that the drug response of zero-dose arm µ0 is not included in the inequality.
The drug effect at dose level di is defined as θi = µi − µ0, the relative therapeutic effect
of the experiment drug compared to the placebo or active control. It is obvious that the dose
effects defined in this way also satisfy the inequality θ1 > θ2 > . . . > θk. The simultaneous
confidence intervals with 1− α coverage probability are defined as
P{θi ∈ (li, ui) : i = 1, 2, . . . , k} = 1− α (2.1)
Notice that estimates of θi, 1 6 i 6 k, will be correlated because all are measured
relative to the same control. In this chapter, we will introduce an approach to derive the
simultaneous confidence intervals based on the above relative dose effect variables using a
max-min procedure and the maximum modulus of the multivariate distribution. The max-
min procedure was first suggested by Korn [14](1982) to construct simultaneous confidence
intervals for independent dose response variables under isotonic restriction. We will prove
that this approach can be extended to correlated dose response variables.
It is well known that Tukey’s procedure based on the Studentized range distribution
and Scheffe´’s procedure based on the F -distribution enable us to make multiple comparisons
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among a set of sample means while controlling the overall simultaneous probability coverage.
However, in practice we often only need to make comparisons between one common control
and each of the experimental treatment groups. In our case, as well as in many other
practical applications, we also have prior knowledge about the order of the expected means
of treatment groups. Although procedures by Tukey and Scheffe´ still apply, they are too
conservative and it is possible to derive more precise confidence intervals.
2.3 LITERATURE REVIEW
One of the earliest attempts to increase the efficiency of Scheffe´’s confidence bounds for mul-
tiple comparisons by incorporating additional information was by Bohrer in 1967. Bohrer [3]
suggested in his paper a sharper extension of Scheffe´’s confidence bounds for linear functions
of independent normal random variables when assuming all coefficients of the linear function
are nonnegative. Bohrer gave tables of the critical values, and also showed that when the
sample size is large, the common width of the improved simultaneous confidence bounds is
about 70.7% of the common width of Scheffe´ ’s confidence bounds.
Marcus et al [19](1976) developed flexible simultaneous lower confidence bounds for the
means in a one-way ANOVA model when the means are restricted to a certain subset of
Rk as long as this subset is closed under multiplication by a positive scalar. They gave the
result when all means are nonnegative and the result when the means are ordered. Marcus
[17](1982) pointed out that the approach can also be used to obtain two-sided simultaneous
confidence intervals.
D. A. Williams [36](1977) discussed the limiting distributions of the estimated maximum
and range of a set of ordered normal means when all means are in fact equal. Williams showed
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that approximate 1 − α simultaneous confidence intervals for all ordered contrasts of the
normal means can be obtained by using the percentile points of these limiting distributions.
Dunnett [8] [9](1955 and 1964) developed an approach to obtain simultaneous confidence
intervals for comparing the means of multiple treatment groups to the mean of a common
control group when the response variable is normally distributed with all groups having a
common variance. Tables of exact critical values for one-sided and two-sided confidence
limits are given when the assumed common variance σ2 is known or when it is not known.
In problems when the outcome is a proportion, which is the case in a lot of clinical studies,
a variable transformation yj = arcsin p
1/2
j of the same proportions p can be used. When
the sample sizes nj within each group are reasonably large, yj can be treated as normally
distributed with variance σ2 = 1
4
.
Korn [14](1982) proposed a simple procedure using a modification of the Studentized
maximum modulus technique to construct confidence bands for dose-responses under nonde-
creasing order restriction. This procedure assumes no parametric model for the dose-response
curves.
Schoenfeld [22] (1986) suggested using the intersection of a 1 − α confidence region for
the mean response vector (µ1, µ2, . . . , µk) and the set of all monotone non-decreasing or non-
increasing functions on dose levels to construct 1 − α simultaneous confidence intervals for
µi.
Hayter [12](1990) proposed to use a one-sided studentized range test (OSRT) to con-
struct a simultaneous lower confidence bound for all ordered pair-wise contrasts. C. C. Lee
[15](1996) improved Korn’s procedure by introducing the distribution of a generalization of
the maximum modulus.
Our review of methodology research in the literature tells us that although extensive work
10
has been done in the area of simultaneous confidence intervals under the restriction of isotonic
dose response, results have been almost exclusively limited to the assumption of independent
dose response variables. However, as I will argue later, this assumption often fails to hold in
applications. Dose response variables are usually correlated. Thus developing simultaneous
confidence intervals under order restrictions for correlated dose response variables can have
practical importance. In the next section I will give an detailed discussion of Korn’s max-min
procedure because it is closely related to the approach I will propose in this chapter.
2.4 KORN’S MAX-MIN PROCEDURE
Korn’s [14](1982) procedure using a modification of the Studentized maximum modulus
technique provides a simple, intuitive, yet efficient way to construct simultaneous confidence
intervals under order restriction. This procedure assumes no parametric model for the dose-
response curves. Here, we will briefly introduce this procedure and will also provide the
proof of Korn’s claim under more general conditions.
Suppose dose response data yi1, yi2, . . . , yini are collected at dose level xi, i = 1, . . . , k.
The yij are assumed to be normally distributed with mean f(xi) and common unknown
variance σ2, and write y¯i as the sample mean of dose group i. Model-free simultaneous 1−α
confidence intervals are given by
y¯i −mk,n−ks/√ni 6 f(xi) 6 y¯i +mk,n−ks/√ni (2.2)
for i = 1, 2, . . . , k, where s2 is the usual pooled estimate of the variance σ2, and mk,n−k is the
upper α point of the Studentized maximum modulus distribution with parameters k, n− k.
If the dose-response curve f(x) is known to be non-decreasing, then the above confidence
11
intervals can be modified as
max
l6i
{y¯l −mk,n−ks/√nl} 6 f(xi) 6 min
j>i
{y¯j +mk,n−ks/√nj} (2.3)
for i = 1, 2, . . . , k. These max-min confidence intervals are derived from the sample means
and the isotonic assumption on f(x): the f(xi) satisfy (2.2) and are a non-decreasing se-
quence if and only if the f(xi) satisfy (2.3). Thus, the simultaneous confidence intervals (2.3)
have exactly 1−α coverage probability. It is possible that these intervals do not contain the
usual isotonic regression estimates, and may even be empty. However, the coverage prob-
ability is true if the monotone assumption is correct. Korn also pointed out at the end of
his paper that the same technique can be used in deriving simultaneous confidence intervals
for contrasts between all doses and a common control using Dunnett’s approach, under the
assumption that the dose response relationship is nondecreasing. However, he didn’t give
further details or examples for the extension.
2.5 SIMULTANEOUS CONFIDENCE INTERVALS FOR MULTIPLE
COMPARISON UNDER RESTRICTION OF ISOTONIC DOSE
RESPONSE
Clinical dose studies in most therapeutic areas are comparative in nature. Subjectiveness of
drug responses, heterogeneity of patient population, uncontrollable effect of different med-
ical practice and continuing development in concomitant medications are among the many
reasons that the absolute drug responses are not very good indication of the actual drug
effect. In these cases, a control group, either a placebo group that receives only a dummy
drug, or an active control group that receives a different treatment (usually some treatment
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commonly used in standard practice), are enrolled in parallel with the experimental drug
group. Randomization and blinding is often used to ensure unbiased and random patient
recruitment. In a comparative dose study, the approach of comparing each dose group to the
common control group, as introduced earlier in this chapter, is the most common analysis
method used.
The following proof shows that the max-min procedure by Korn can be extended to the
cases of correlated isotonic dose response variables:
2.5.0.1 Proof of the Extension of Korn’s Procedure in Correlated dose response
variables: Suppose yi1, yi2, . . . , yini are random normal variables distributed as N(µi, σ),
i = 1, 2, . . . , k, and y¯i is the sample mean. Suppose q
α
k is the critical value for 1 − α
simultaneous confidence interval such that
Pr
(
µ ⊂ Q) = 1− α (2.4)
where
Q = {y¯i − qαk σ/
√
ni 6 µi 6 y¯i + qαk σ/
√
ni, i = 1, 2, . . . , k} (2.5)
Now additionally suppose that we know the order restriction that (µ1, µ2, . . . µk) ∈ O,
where O = (µ1 6 µ2 6 . . . ,6 µk) ∩Rk, and we define the confidence set Q˜ as:
Q˜ = { max
l6i
{y¯l − qαk σ/
√
nl} 6 µi 6 min
j>i
{y¯j + qαk σ/
√
nj},
i = 1, 2, . . . , k }
It is obvious that Q˜ ⊆ Q. Therefore
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Pr{(µ1, µ2, . . . µk) ∈ Q˜}
6 Pr{(µ1, µ2, . . . µk) ∈ Q}
= 1− α.
On the other hand, for any point A = (a1, a2, . . . , ak) ∈ O ∩Q:
A ∈ O ⇒ a1 6 a2 . . . 6 ak
A ∈ Q ⇒ y¯i − qαk σ/
√
ni 6 ai 6 y¯i + qαk σ/
√
ni, i = 1, 2, . . . , k
So the point A has to satisfy
max
l6i
{y¯l − qαk σ/
√
nl} 6 ai 6 min
j>i
{y¯j + qαk σ/
√
nj}, i = 1, 2, . . . , k
⇒ A ∈ Q˜
In other words, Q ∩ O ⊆ Q˜. Since we already know (µ1, µ2, . . . µk) ∈ O, the following is
also true:
Pr{(µ1, µ2, . . . µk) ∈ Q˜}
> Pr{(µ1, µ2, . . . µk) ∈ Q ∩O}
= Pr{(µ1, µ2, . . . µk) ∈ Q}
= 1− α
Therefore we have proven that the simultaneous confidence interval Q˜ is the exact con-
fidence set:
Pr{(µ1, µ2, . . . µk) ∈ Q˜} = 1− α
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under the order restriction µ1 6 µ2 6 . . . ,6 µk. Notice that the proof doesn’t require that
the yij’s have to be independent, nor does it require that the variances have to be the same.
In fact, the max-min procedure can also be expressed as
Q˜ = { inf{µi : (µ1, µ2, . . . , µk) ∈ Q ∩O}
6 µi 6
sup{µi : (µ1, µ2, . . . , µk) ∈ Q ∩O}, i = 1, 2, . . . , k}.
The proof is valid for any convex subset O of the parameter space, where a convex subset
guarantees that the resulting simultaneous confidence intervals are dense. Therefore the
above inequality can be applied to other similar distributions such as the multivariate t-
distribution when the σ2i ’s are not known. Korn [14] studied the efficiency achieved by using
the max-min procedure for independent normal distributions. Korn’s simulation result show
that when the means are in fact equal, the max-min procedure can reduce the average width
of the simultaneous confidence intervals of six normal means by approximately 30%, and the
reduction increases to approximately 50% for ten normal means.
2.5.1 Critical Values of Simultaneous Confidence Intervals for Correlated Dose
Response Variables
Dunnett’s [8] [9] results provided the critical values for comparing multiple treatment groups
to a common control. But Dunnett’s approach only applies to the cases where all the observed
treatment groups’ responses have the same variance σ2t , although it allows a different variance
σ2c in the common control group. This translates into the simple equicorrelated covariance
structure. Even in cases when it is usually reasonable to assume equal variance of drug
response among treatment groups, with the increasing use of adaptive study designs, we
often have different sample sizes among the treatment groups. Thus the estimated drug
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response variables have different variances, and the resulting covariance matrix often has
complicated and unpredictable structure.
Somerville [24][25](1997 and 2001) developed computation methodology to calculate the
critical values for a large class of simultaneous confidence intervals. Given k populations with
unknown means µi, i = 1, 2, . . . , k, assume that the location parameter estimates xi have a
joint multivariate normal distribution with mean µ and non-singular covariance matrix σ2Σ
with Σ known and s2 an independent estimate of σ2 with ν degrees of freedom. Suppose
B = {c1, c2, . . . , cm} is a finite collection of linear functions of the xi’s. Somerville shows
that, his approach can solve for the critical value q such that
Pr
(
c′ix/ (var(c
′
ix))
1/2 ≤ q/
√
2 : ci ∈ B, i = 1, 2, . . . ,m
)
= 1− α (2.6)
for arbitrary values for ci,m, k, ν,Σ within acceptable computing time on computers with
Pentium III processor. Critical values for a large class of simultaneous intervals can be
obtained using this approach, including Tukey’s all pairwise comparisons, Dunnett’s one-
sided and two-sided comparisons with a control, Williams-type comparisons, Marcus-type
comparisons, Hayter’s one-sided simultaneous confidence intervals and others.
Using a computer program based on Somerville’s computing algorithm, critical values
for simultaneous confidence intervals of correlated dose responses variables can be easily
obtained by specifying appropriate covariance structure and contrast vectors. In a typical
dose response study as described at the beginning of the Chapter, k dose groups and a
common control group are used, and the dose response in each group is assumed to be
normally distributed with means µ0, µi, i = 1, 2, . . . , k and variance σ
2
i . The drug effect at
each dose group is measured as θi = µi − µ0, i = 1, 2, . . . , k. Suppose the study design
allocates sample size ni to group i, i = 1, 2, . . . , k. The observed drug effects at each dose
x¯i = y¯i−y¯0, i = 1, 2, . . . , k, have a multivariate normal distribution with mean (θ1, θ2, . . . , θk),
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and covariance matrix Σ, whose diagonal elements are σ2ii = σ
2
i /ni+ σ
2
0/n0, and off-diagonal
elements are σ2ij = σ
2
0/n0 (i 6= j). Although the covariances are all the same between
each pair of dose effect estimates, the correlation coefficients are different unless all the dose
groups have the same sample size. The relative dose effect can also be viewed as applying the
contrast matrix (c1, c2, . . . , ck) to dose response (µ0, µ1, . . . , µk), where each ci is a contrast
vector with first element equal to −1, ith element equal to 1, and all the rest are zeros.
The computing algorithm can be used to calculate the boundary values for the 1 − α
simultaneous confidence intervals of k dose effect estimates, say qαρ,k, such that
P{ y¯i − y¯0 − qαρ,k(σi
√
1/ni + σ0
√
1/n0) ≤ θi ≤ y¯i − y¯0 + qαρ,k(σi
√
1/ni + σ0
√
1/n0),
i = 1, 2, . . . , k } = 1− α (2.7)
We assume the isotonic restriction on dose effect such that θ1 > θ2 > . . . > θk. By
applying the max-min procedure, we have the following simultaneous confidence intervals
under isotonic dose response restriction
max
l6i
{y¯l − y¯0 − qαρ,k(σl
√
1/nl + σ0
√
1/n0)}
6 µi − µ0 6
min
j>i
{y¯j − y¯0 − qαρ,k(σj
√
1/nj + σ0
√
1/n0)}, i = 1, 2, . . . , k (2.8)
The computing algorithm is Monte-Carlo simulation based and can achieve extremely
high accuracies of critical values by increasing the Monte-Carlo sampling sizes. Therefore,
under correct assumption of multivariate normal distributions, the above simultaneous con-
fidence intervals can be treated as having the exact coverage probability 1− α.
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2.6 APPLICATION OF THE GENERAL MAX-MIN APPROACH TO
BINARY DOSE RESPONSE DATA
In this chapter we will apply the approach of simultaneous confidence intervals in a clinical
trial with the endpoint defined as a binary variable. In the dose study we introduced in
Chapter 1, the binary outcome can be defined as the occurrence of death, MI and/or urgent
revascularization of the target coronary vessel within certain period after cardiovascular drug
treatment, or the treatment success defined as successful reduction of vessel stenosis.
2.6.1 Measurements of Drug Effect for Binary Dose Response
Let pi be the observed event rate at dose i and let p0 be the event rate for the control group,
the drug effect at each dose relative to control treatment can be measured using one of the
following four measurements:
• Difference of observed event rate between each dose level and the control: (pi − p0).
• Difference of arcsine of the square root of event rate (arcsin p
1
2
i − arcsin p
1
2
0 ).
• The log odds ratio between each dose level and the control (ln pi(1−p0)
(1−pi)p0 ).
• Log of Relative risk between each dose level and the control (ln pi/p0).
Although Brown et al [5] showed that the coverage probability of normal-approximation-
based confidence intervals for binomial data can be unstable for even moderate sample size, he
also pointed out that relative measures such as difference of proportions perform much better.
Therefore, we propose to use the normal distribution based approach we have developed to
obtain simultaneous confidence intervals for the above four comparisons. The covariance
matrix for each of the four measurements can be easily identified with the knowledge of
sample sizes in the treatment groups. Suppose the sample size in dose group i is ni, the
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corresponding number of observed adverse events is mi, and the estimated event rate pˆi =
mi/ni, i = 0, 1, 2, . . . , k. The estimated covariances of the approximate multivariate normal
distributions of the above four measurements of the estimated relative dose effects at dose 1
to k are:
• (pi − p0): σii = pˆi(1−pˆi)ni +
pˆ0(1−pˆ0)
n0
, σij(i6=j) =
pˆ0(1−pˆ0)
n0
• (arcsin p
1
2
i − arcsin p
1
2
0 ): σii =
1
2
, σij(i6=j) = 14
• (ln pi(1−p0)
(1−pi)p0 ): σii =
1
ni−mi +
1
mi
+ 1
n0−m0 +
1
m0
, σij(i6=j) = 1n0−m0 +
1
m0
• (ln pi/p0): σii = 1−pˆimi +
1−pˆ0
m0
, σij(i6=j) =
1−pˆ0
m0
2.6.2 Simulation Study
The above four different measures of drug effect are explored. Continuity adjustment is done
by adding 0.5 to the event count. Ten different monotone dose response configurations for
six dose levels are used, and 5000 Monte Carlo simulations are used in each case. The true
event rates for each dose response configuration are as follows:
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Dose Response
Configuration Control Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6
1 0.10 0.10 0.10 0.10 0.10 0.10 0.10
2 0.10 0.12 0.12 0.12 0.12 0.12 0.12
3 0.10 0.08 0.08 0.08 0.08 0.08 0.08
4 0.10 0.12 0.11 0.10 0.09 0.08 0.07
5 0.10 0.12 0.12 0.10 0.10 0.08 0.08
6 0.10 0.12 0.12 0.12 0.08 0.08 0.08
7 0.10 0.09 0.08 0.07 0.06 0.05 0.04
8 0.10 0.17 0.16 0.15 0.14 0.13 0.12
9 0.10 0.12 0.08 0.08 0.08 0.08 0.08
10 0.10 0.12 0.12 0.12 0.12 0.12 0.08
These dose response configurations include flat dose response (1 2 3), linear dose response
(4 7 8) and step dose response (5 6 9 10). Table 1 compares the critical values of simultane-
ous confidence intervals for correlated multivariate normal means obtained by Somerville’s
simulation algorithm and those provided by Dunnett [9], Tukey and Hayter. Covariance
matrices used were based on the dose configurations and drug response measurements. For
measurements using relative risk pi/p0 or difference of risk pi−p0, the covariance matrix also
depends on the sample estimates of event rate. However, we calculated the critical values
based on the known true probabilities for the purpose of comparison. When using simulation
to validate the coverage probabilities (Table 2-7), we calculate the critical values based on
the sample probabilities from each random sample. It can be seen that the critical values we
have calculated in most cases are fairly close to Dunnett’s approach. However, the confidence
intervals based on the exact critical values when the actual covariance structure is taken into
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consideration have generally more accurate coverage probability (Table 2). Given easy and
relatively fast computation and the wide availability of high-speed micro computers, the
exact critical values definitely are preferred.
Simulation results of the coverage probability of 95% simultaneous confidence intervals
are presented in Table 2 to Table 7. The results in Tables 2 to 5 are based on sample sizes
of 1500 in the control group, 500 in the first two or four dose groups, and 1000 in the last
four or two dose groups. These sample sizes reflect a simple adaptive design that assigns
more subjects to higher dose groups and the control group to increase overall efficiency.
The simultaneous confidence intervals obtained using the max-min procedure and critical
values based on correlated normal means perform the best (Table 2). The actual coverage
probabilities are very close to 95% even with moderate sample size, and are consistent across
different dose response configurations. The results from using Dunnet’s critical values are
not far off (Table 3), but are clearly not as accurate. On the other hand, we can also see
that the simultaneous confidence intervals using Hayter’s approach (Table 4) and Tukey’s
approach (Table 5) are too conservative, usually having actual coverage probability from
0.965 to 0.985.
It is well known that the normal approximation approach for binary variables usually does
not perform well when the sample sizes are small, or when the expected binomial proportions
are close to 0 or 1. Table 2.6 lists the simulation results when the sample sizes for each group
are reduced by 90%, i.e., 150 in the control group, 50 in the first two or four dose groups,
and 100 in the last four or two dose groups. It is comforting to see that the performance
is actually fairly good. Table 2.7 lists the simulation results when the binomial proportions
for control and each dose group are cut by 50%. The control group has expected event rate
at 5%, and so on. When the drug effect is measured as differences between event rates or
differences between arcsin square root of event rates, the coverage probabilities are still close
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Table 1: Critical Values for Simultaneous Confidence Intervals
Dose Config. pi − p0 arcsin p
1
2
i − arcsin p
1
2
0 ln
pi(1−p0)
(1−pi)p0 ln pi/p0
Sample Size: Control=1500 Doses 1-2=500 Dose 3-6=1000
1 2.60232 2.60225 2.60232 2.56773
2 2.60828 2.60225 2.59280 2.55457
3 2.59310 2.60225 2.61098 2.58045
4 2.59894 2.60225 2.60523 2.57180
5 2.60113 2.60225 2.60337 2.56769
6 2.60038 2.60225 2.60392 2.56849
7 2.58011 2.60225 2.61753 2.59227
8 2.61238 2.60225 2.58213 2.54110
9 2.59607 2.60225 2.60867 2.57656
10 2.59604 2.60225 2.60766 2.57698
Sample Size: Control=1500 Doses 1-4=500 Dose 5-6=1000
1 2.60996 2.60990 2.60996 2.56773
2 2.61459 2.60990 2.60308 2.55457
3 2.60332 2.60990 2.61662 2.58045
4 2.60734 2.60990 2.61267 2.57180
5 2.60920 2.60990 2.61130 2.56769
6 2.60909 2.60990 2.61086 2.56849
7 2.59297 2.60990 2.62135 2.59227
8 2.61749 2.60990 2.59450 2.54110
9 2.60538 2.60990 2.61427 2.57656
10 2.60594 2.60990 2.61420 2.57698
Dunnett=2.61611 Hayter=2.82734 Tukey=3.02916
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Table 2: Coverage Probability(%) of 95% Simultaneous Confidence Intervals of Correlated
Dose Response
Dose Config. pi − p0 arcsin p
1
2
i − arcsin p
1
2
0 ln
pi(1−p0)
(1−pi)p0 ln pi/p0
Sample Size: Control=1500 Doses 1-2=500 Dose 3-6=1000
1 0.94666 0.94758 0.94614 0.95166
2 0.94650 0.94778 0.94438 0.95142
3 0.94508 0.94628 0.94544 0.95134
4 0.94576 0.94686 0.94554 0.95140
5 0.94600 0.94700 0.94446 0.95094
6 0.94644 0.94860 0.94648 0.95250
7 0.94586 0.94610 0.94780 0.95196
8 0.94834 0.94918 0.94424 0.95270
9 0.94648 0.94772 0.94706 0.95216
10 0.94438 0.94758 0.94700 0.95308
Sample Size: Control=1500 Doses 1-4=500 Dose 5-6=1000
1 0.94306 0.94518 0.94500 0.95092
2 0.94362 0.94608 0.94366 0.95088
3 0.94012 0.94328 0.94406 0.95052
4 0.94272 0.94464 0.94466 0.95040
5 0.94228 0.94436 0.94310 0.94928
6 0.94350 0.94624 0.94542 0.95158
7 0.94090 0.94338 0.94700 0.95096
8 0.94678 0.94782 0.94252 0.95140
9 0.94276 0.94572 0.94606 0.95158
10 0.94096 0.94508 0.94530 0.95142
23
Table 3: Coverage Probability(%) of 95% Simultaneous Confidence Intervals Using Dunnett’s
Critical value
Dose Config. pi − p0 arcsin p
1
2
i − arcsin p
1
2
0 ln
pi(1−p0)
(1−pi)p0 ln pi/p0
Sample Size: Control=1500 Doses 1-2=500 Dose 3-6=1000
1 0.94086 0.94212 0.94616 0.94668
2 0.94020 0.94292 0.94628 0.94746
3 0.94114 0.94028 0.94452 0.94442
4 0.94106 0.94158 0.94536 0.94604
5 0.94036 0.94116 0.94458 0.94564
6 0.94164 0.94316 0.94650 0.94720
7 0.94336 0.94048 0.94468 0.94448
8 0.94154 0.94378 0.94910 0.95026
9 0.94180 0.94184 0.94632 0.94648
10 0.93946 0.94150 0.94600 0.94718
Sample Size: Control=1500 Doses 1-4=500 Dose 5-6=1000
1 0.93710 0.93972 0.94502 0.94528
2 0.93696 0.94102 0.94536 0.94684
3 0.93622 0.93706 0.94346 0.94292
4 0.93768 0.93990 0.94436 0.94472
5 0.93660 0.93864 0.94318 0.94394
6 0.93874 0.94050 0.94552 0.94570
7 0.93824 0.93758 0.94398 0.94388
8 0.94002 0.94220 0.94712 0.94840
9 0.93840 0.94002 0.94560 0.94544
10 0.93666 0.93928 0.94442 0.94574
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Table 4: Coverage Probability(%) of 95% Simultaneous Confidence Intervals Using Hayter’s
Critical Valus
Dose Config. pi − p0 arcsin p
1
2
i − arcsin p
1
2
0 ln
pi(1−p0)
(1−pi)p0 ln pi/p0
Sample Size: Control=1500 Doses 1-2=500 Dose 3-6=1000
1 0.96158 0.96384 0.96670 0.96710
2 0.96206 0.96362 0.96728 0.96754
3 0.96178 0.96148 0.96554 0.96532
4 0.96196 0.96254 0.96536 0.96538
5 0.96122 0.96268 0.96612 0.96626
6 0.96252 0.96336 0.96672 0.96672
7 0.96366 0.96184 0.96568 0.96526
8 0.96358 0.96604 0.96930 0.97030
9 0.96242 0.96258 0.96616 0.96632
10 0.96190 0.96394 0.96718 0.96742
Sample Size: Control=1500 Doses 1-4=500 Dose 5-6=1000
1 0.95886 0.96236 0.96648 0.96680
2 0.95930 0.96208 0.96636 0.96618
3 0.95792 0.95976 0.96564 0.96502
4 0.95884 0.96096 0.96532 0.96538
5 0.95836 0.96084 0.96558 0.96552
6 0.95960 0.96220 0.96616 0.96594
7 0.96020 0.95944 0.96572 0.96494
8 0.96178 0.96524 0.96866 0.96934
9 0.95910 0.96092 0.96604 0.96582
10 0.95856 0.96216 0.96662 0.96656
25
Table 5: Coverage Probability(%) of 95% Simultaneous Confidence Intervals Using Tukey’s
Critical Value
Dose Config. pi − p0 arcsin p
1
2
i − arcsin p
1
2
0 ln
pi(1−p0)
(1−pi)p0 ln pi/p0
Sample Size: Control=1500 Doses 1-2=500 Dose 3-6=1000
1 0.97934 0.98020 0.98306 0.98306
2 0.97842 0.98042 0.98242 0.98284
3 0.97878 0.97954 0.98200 0.98248
4 0.97896 0.97974 0.98200 0.98212
5 0.97866 0.97944 0.98186 0.98214
6 0.97952 0.98014 0.98194 0.98242
7 0.97922 0.97836 0.98148 0.98158
8 0.98078 0.98216 0.98450 0.98476
9 0.97900 0.97940 0.98194 0.98236
10 0.97916 0.98044 0.98226 0.98240
Sample Size: Control=1500 Doses 1-4=500 Dose 5-6=1000
1 0.97754 0.97964 0.98290 0.98294
2 0.97636 0.97970 0.98206 0.98258
3 0.97646 0.97872 0.98170 0.98226
4 0.97696 0.97884 0.98198 0.98192
5 0.97642 0.97834 0.98164 0.98172
6 0.97714 0.97922 0.98178 0.98234
7 0.97640 0.97744 0.98146 0.98148
8 0.97946 0.98180 0.98366 0.98398
9 0.97664 0.97858 0.98214 0.98254
10 0.97704 0.97960 0.98194 0.98232
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Table 6: Coverage Probability(%) of 95% Simultaneous Confidence Intervals of Correlated
Dose Response with Smaller Sample Size
Dose Config. pi − p0 arcsin p
1
2
i − arcsin p
1
2
0 ln
pi(1−p0)
(1−pi)p0 ln pi/p0
Sample Size: Control=150 Doses 1-2=50 Dose 3-6=100
1 0.94602 0.94998 0.96940 0.97368
2 0.94414 0.94546 0.96612 0.97304
3 0.95320 0.94590 0.96578 0.96824
4 0.94860 0.95152 0.96990 0.97366
5 0.94630 0.94812 0.96752 0.97142
6 0.94872 0.94682 0.96900 0.97272
7 0.95380 0.94932 0.96250 0.96142
8 0.93914 0.94754 0.96482 0.97448
9 0.95008 0.94676 0.96750 0.97008
10 0.94392 0.94690 0.96950 0.97384
Sample Size: Control=150 Doses 1-4=50 Dose 5-6=100
1 0.94042 0.94764 0.96688 0.96916
2 0.93640 0.94502 0.96498 0.96858
3 0.94662 0.94450 0.96200 0.96020
4 0.94226 0.94882 0.96562 0.96752
5 0.93980 0.94472 0.96550 0.96700
6 0.93988 0.94564 0.96608 0.96684
7 0.94948 0.94994 0.95558 0.95266
8 0.93206 0.94572 0.96536 0.97294
9 0.94340 0.94504 0.96376 0.96256
10 0.93704 0.94662 0.96706 0.96966
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Table 7: Coverage Probability(%) of 95% Simultaneous Confidence Intervals of Correlated
Dose Response with 50% Smaller Expected Event Rates
Dose Config. pi − p0 arcsin p
1
2
i − arcsin p
1
2
0 ln
pi(1−p0)
(1−pi)p0 ln pi/p0
Sample Size: Control=1500 Doses 1-2=500 Dose 3-6=1000
1 0.94208 0.94464 0.94764 0.95352
2 0.94308 0.94540 0.94574 0.95330
3 0.93968 0.94150 0.94864 0.95408
4 0.94150 0.94410 0.94786 0.95252
5 0.94222 0.94436 0.94700 0.95266
6 0.94338 0.94526 0.94818 0.95374
7 0.94134 0.94008 0.95018 0.95434
8 0.94420 0.94768 0.94638 0.95420
9 0.94118 0.94402 0.94950 0.95476
10 0.93966 0.94512 0.94960 0.95426
Sample Size: Control=1500 Doses 1-4=500 Dose 5-6=1000
1 0.93618 0.94184 0.94684 0.95340
2 0.93876 0.94298 0.94636 0.95228
3 0.93314 0.93736 0.94854 0.95340
4 0.93646 0.94176 0.94708 0.95236
5 0.93662 0.94142 0.94568 0.95174
6 0.93808 0.94224 0.94786 0.95330
7 0.93486 0.93700 0.95088 0.95482
8 0.93758 0.94374 0.94414 0.95138
9 0.93402 0.94066 0.94878 0.95452
10 0.93314 0.94206 0.94892 0.95318
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to the target of 95%. But the simultaneous confidence intervals are rather conservative when
odds ratios or relative risks are used. In cases where one of these two measures is desired,
methods using the exact binomial distributions can be used to obtain the boundary points
of confidence intervals at all dose levels, and similar max-min procedures can be applied to
derive the simultaneous confidence intervals of the isotonic dose responses.
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3.0 STEPDOWN TESTING PROCEDURES FOR DOSE FINDING STUDY
WITH ADAPTIVE DESIGN
3.1 INTRODUCTION
The problem of identifying the lowest effective drug dose for which the mean response is
superior to that at the control group is often an important issue in a drug efficacy study.
Likewise, one of the most important goals in a toxicity study is to identify the highest safe
dose, which is defined as the highest safe drug dose for which the mean safety response is not
worse than that at the control group. Stepdown testing procedure is a widely used approach
in this area. Under the assumption of a monotone mean configuration, the stepdown testing
procedure is particularly powerful and easy to perform. In this chapter we will concentrate
on the dose studies for finding the lowest effective dose. The testing approach for finding
the highest safe dose can be formulated in exactly the same way.
Suppose the drug response variables have means µi at dose levels di, i = 1, 2, . . . , k, and
µ0 is the mean drug response of the control group. Drug efficacy is measured as the relative
drug response such as µi−µ0. Write the means of relative drug efficacy as θi, i = 1, 2, . . . , k.
Dose level di is defined to be effective if θi > 0. Notice that the dose responses don’t have
to be independent of each other, as we have discussed in the previous chapter. Suppose
that we can assume θ1 6 θ2 6 . . . 6 θk. Then dE is the lowest effective dose if θj 6 0 for
j < E and θj > 0 for E 6 j 6 k. In practice, people usually define the lowest effective
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dose in a dose study as dose level dE if θj 6 0 for j < E and θj > δ(δ > 0) for E 6 j 6 k.
δ here is usually referred to as the smallest (clinically) meaningful drug effect. The use
of δ is useful in comparing statistical approaches, because no statistically procedure can
discriminate between the effective and noneffective dose groups if the means of the dose
effects can be arbitrarily close to each other [31].
The design and validity of a stepdown testing procedure to find the lowest effective dose
level follows a general procedure given by Marcus, Peritz and Gabriel [18]. For a family
of hypotheses {H0i : i = 1, 2, . . . , k} in a multiple testing problem, the family-wise error
rate(FWE) is defined as
FWE = Pr{at least one trueH0i is rejected}.
A step testing procedure controls the family-wise error rate strongly if FWE is controlled
when any subgroup of the family of null hypothese are true. If a step testing procedure
satisfies the conditions of closed procedure, which we will define in section 3.3, the procedure
controls the family-wise error rate strongly.
3.2 LITERATURE REVIEW ON STEPWISE TESTING PROCEDURE IN
DOSE STUDY
Stepwise testing procedures in dose study with isotonic dose responses have been extensively
researched. The earliest well known result is by Williams [34] [35] (1971 and 1972). Williams
proposed a stepwise testing procedure to compare the mean responses of k dose levels with a
zero-dose control by using the isotonic regression estimates. The table of upper α percentage
points of the distribution of the comparisons is provided by Williams for equal allocation of
subjects (1971) and for unequal allocation of subjects (1972).
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Tamhane et al [28](1996) did a comparison study of the stepwise testing procedures using
William’s approach and various linear contrasts. He showed that William’s procedure, the
stepdown procedure using Helmert Contrast and critical value of correlated t-statistics, and
the stepdown procedure using linear contrast and critical value for simple t-statistics have
the highest average powers, and their performances are relatively stable for different values
of MED (Minimum Effective Dose), δ (smallest meaningful difference between treatment and
control) and the type of dose response function.
Bauer [1] (1997) in a follow-up paper pointed out that the strong control of family-wise
Type I error rate is guaranteed in stepwise procedures only if monotone order restriction is
assumed to hold among response means. The claim made by Tamhane [28] et al (1996) that
the monotone assumption in response means is not required is only true for many-to-one
pairwise comparisons.
Bauer et al [2] (2001) proposed stepwise procedures when both efficacy and safety need
to be considered. A stepwise procedure for suitably defined subfamilies is used to control
the overall family-wise error, and order restrictions for both efficacy and safety are assumed.
Similarly, Tamhane et al [29] (2002) provided a stepwise testing procedure for detecting the
minimum effective (MINED) and maximum safe dose (MAXSD) using the joint t-distribution
of efficacy response and safety response variables at each dose level.
Channon et al [6] (2001) pointed out that although stepdown testing procedures provide
powerful tools for identifying the minimum effective and/or maximum safe dose, simultaneous
inference about dose responses after the testing is still desirable in practice. Channon et al
performed simulation studies to compare the actual coverage of the proposed simultaneous
confidence intervals. It is shown that although the minimum coverage is not theoretically
guaranteed, the actual coverage ranges from 93% to 97%, which should be satisfactory for
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practical purposes.
Bretz et al [4] (2003) suggested that usually the relative difference between treatments
and control is of interest instead of absolute measures of treatments. They proposed to
conduct stepdown procedures based on the ratio of the drug responses between each dose
level and the control.
One common shortcoming of the previous research is that the proposed testing procedures
have implicitly assumed that the dose study data are randomly collected from the probability
distributions. In a clinical study with adaptive design, this assumption is not correct because
the data collected are not totally random samples. It is necessary to tailor stepwise testing
procedures for non-random samples in order to draw valid statistical inference. We will try
to address this problem in this chapter.
3.3 CLOSED TESTING PROCEDURE
Let {H0i : 1 ≤ i ≤ k} be a finite family of null hypotheses. One can form the closure of this
family by taking all the nonempty intersections H0p =
⋂
i∈P H0i for ∅ ⊂ P ⊆ {1, 2, . . . , k}.
If an α-level test of each hypothesis H0p is available, then a closed testing procedure can be
constructed by rejecting any null hypothesis H0p only if every H0q is rejected by its associated
α-level test for all H0q ⊇ H0p. As pointed out by Marcus et al [18](1976), a closed testing
procedure strongly controls the Type I family-wise error probability in multiple comparisons,
i.e., the Type I family-wise error probability is controlled under any configuration of the null
hypotheses family.
Suppose in a dose study, one can assume that the drug responses at control group and
dose levels 1 to k are normal random variables with the means as µi, i = 0, 1, 2 . . . , k, and
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a common variance σ2. One can further assume that µ1 6 µ2 6 . . . 6 µk. Suppose that
the drug effect at each dose level is defined as the difference between the drug response of
the control and each dose group: θi = µi − µ0, i = 1, 2, . . . , k. We can estimate the mean
drug effects by sample mean differences y¯i− y¯0, i = 1, 2, . . . , k, with corresponding standard
errors as ( 1
n0
+ 1
ni
)
1
2σ, where n0, n1, . . . , nk are the sample sizes in each group correspondingly.
Consider the family of null hypotheses H0i : 0 > θi > θi−1 > . . . > θ1, i = 1, 2, . . . , k, and the
corresponding alternative hypotheses H1i : θi > 0. It is obvious that, under the isotonic dose
response µ1 6 µ1 6 . . . 6 µk, the set of all null hypotheses form a closure since it contains
the intersections of all possible subsets of the family of the null hypotheses. In fact, we have
H0k ⊇ H0k−1 ⊇ . . . ⊇ H01. Write Z1−α as the 1− α percentile point of the standard normal
distribution. The following stepdown one-sided testing procedure is a closed procedure and
strongly controls the Type I family-wise error probability at level of α:
• If y¯k − y¯0 6 ( 1nk + 1n0 )
1
2σZ1−α, then accept the null hypothesis H0k and stop the testing
procedure;
else then reject H0k and go to the next step.
• If y¯k−1 − y¯0 6 ( 1nk−1 + 1n0 )
1
2σZ1−α, then accept the null hypothesis H0k−1 and reject H0k,
and stop the testing procedure;
else then reject H0k and H0k−1 and go to the next step.
• · · · · · ·
• If y¯1 − y¯0 6 ( 1n1 + 1n0 )
1
2σZ1−α, then accept H01 and reject H0k, H0k−1, . . . , H02, and stop
the testing procedure;
else then reject H0k, . . . , H01 and stop the testing procedure.
Proposition 3.3.1. The above stepdown testing procedure strongly controls the family-wise
error rate.
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Proof.
Suppose that for the k dose levels, we have the set of true null hypotheses T such that,
0 > θj > θj−1 > . . . > θ1, for j ∈ T . Let J = max{j : j ∈ T}. Write ω as the event that at
least one true null hypothesis is rejected, and ωJ as the event that H0J is rejected. By the
definition of the stepdown procedure, we know that we have to reject H0J in order to reject
any H0i, i ∈ T . Therefore we have
ω ⊆ ωJ ⇒
Pr{ω} 6 Pr{ωJ} ⇒
Pr{Reject any true null hypothesis} 6 Pr{RejectH0J}
= α
Although the above proof does not use the order restriction assumption about the means
of dose responses, the construction of the closed family of null hypotheses H0i,i ∈ 1, 2, . . . , k,
has implicitly used the assumption.
3.4 MODIFIED STEPDOWN TESTING PROCEDURES IN ADAPTIVE
SAMPLING
In studies using adaptive designs, the usual likelihood based approaches for hypothesis testing
and confidence interval are not valid because the data being analyzed are not i.i.d. random
samples from the assumed distributions. Modifications of such approaches are needed to
perform valid statistical analysis for such data. For example, Jennison and Turnbull [13] in
their book discussed approaches to derive statistical inference for the data collected from
adaptive clinical trials.
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For an adaptive design where the study only stops when evidence of null hypothesis
is observed, the actual type I error probability is slightly smaller than the nominal size of
the test when the adaptive sampling is ignored, therefore leading to a conservative testing
procedure. For this reason, in practice people rarely adjust the test for the adaptive sampling.
It is not hard to see that the power of the test also suffers a slight loss too, which people tend
to ignore because the loss is usually insignificant. However, in a stepdown testing procedure
when we are interested in the power to detect the lowest effective dose level, the loss in
the power is exponentially increased when the number of effective dose levels increases, and
should not be ignored. For example, suppose in a single test the power of the accurate test
is 90% and the power of the conservative (unadjusted) test is 87%. The loss of power is
3.33%, which is ignorable. However, in a stepdown test for a dose finding study, if the lowest
effective dose can be as low as the sixth largest dose, the power to find the lowest effective
dose becomes 90%6 = 53% and 87%6 = 43%, correspondingly. The loss of power is increased
to 19%. It is thus important to perform the stepdown test procedure with accurate size that
takes into consideration the adaptive sampling.
In a typical adaptive design for dose study, part of the subjects planned for the dose
group will be enrolled first. If the observed drug effect for a given dose group is smaller than
a certain pre-specified cut point, the rest of the subjects planned for this dose group will
not be enrolled. They can either be allocated to other potentially effective dose groups, or
won’t be enrolled to save resources for other studies. Suppose instead at dose level i, that
the observed drug effect at the first stage is larger than the cut point, then the rest of the
planned subjects for dose i will be enrolled. Usually only the dose groups fully enrolled will
be analyzed as potentially effective dose groups. Also an active control group or a placebo
group are continuously enrolled in parallel with the study drug at each dose group. In an
adaptive dose study like this, the data in each dose group are not random samples and the
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adaptive sampling needs to be incorporated into the data analysis.
Let’s assume the same distributions of drug responses discussed in section 3.2. Let the
cut point for adaptive sampling be λi, i.e., the planned subjects of dose level i will be fully
enrolled if y¯i1− y¯01 > λi, where y¯i1 and y¯01 are sample means of drug responses of dose group
i and the control group after the first stage of the study. The planned sample size and the
sample size at first stage of the study for dose group i are ni and ni1 correspondingly, and
the planned sample size and the sample size enrolled at the first stage of the study in the
control group are n0 and n01 correspondingly. Write the mean drug effect observed at the
first stage and the second stage of dose group i as y¯i1 and y¯i2. Let ni2 = ni − ni1, then
y¯i =
ni1
ni
y¯i1 +
ni2
ni
y¯i2. Also write the mean drug effect observed for the subjects in control
group enrolled after the first stage of the study as y¯02 with sample size n02, then we have
y¯0 =
n01
n0
y¯01 +
n02
n0
y¯0. The 1− α percentile point c1−α for drug effect estimate y¯i − y¯0 can be
obtained by solving
Pr(y¯i − y¯0 > c and y¯i1 − y¯01 > λi)
= Pr(y¯i1 − y¯01 > λi)× Pr(y¯i − y¯0 > c|y¯i1 − y¯01 > λi)
= α (3.1)
Under the null hypothesis H0i, the above probabilities can be expressed separately as
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Pr(y¯i − y¯0 > c|y¯i1 − y¯01 > λi)
=
∫ +∞
λi
fy¯i1−y¯01(w)
1∫ +∞
λi
fy¯i1−y¯0i(v)dv
∫ c
−∞
f(y¯i−y¯0)|y¯i1−y¯0i=w(z)dzdw
and
Pr(y¯i1 − y¯01 > λi) = 1− Φ( λi
σi1
) (3.2)
Here Φ is the cumulative distribution function of standard normal distribution. The condi-
tional densities f(y¯i−y¯0)|(y¯i1−y¯01) can be easily obtained by noticing that under H0i, fy¯i1−y¯01 ∼
N(0, σ
2
ni1
+ σ
2
n01
), fy¯i−y¯0 ∼ N(0, σ
2
ni
+ σ
2
n0
), and y¯i1− y¯01 and y¯i− y¯0 are bivariate normal random
variables with covariance σ
2
ni
+ σ
2
n0
.
3.5 A STEPDOWN TESTING PROCEDURE WITH ADAPTIVE
SAMPLING INFERENCE
In order to take advantage of the power of stepdown testing procedures and also avoid the
bias introduced by adaptive sampling at each dose i, the following stepdown testing approach
is proposed :
• If y¯k1 − y¯0 6 ( 1nk1 +
1
n0
)
1
2σc1−α, then accept the null hypothesis H0k1 and stop the testing
procedure;
else then reject H0k1 and go to the next step.
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• If y¯k1−1 − y¯0 6 ( 1nk1−1 +
1
n0
)
1
2σc1−α, then accept the null hypothesis H0k1−1 and reject
H0k1 , and stop the testing procedure;
else then reject H0k1 and H0k1−1 and go to the next step.
• · · · · · ·
• If y¯1−y¯0 6 ( 1n1+ 1n0 )
1
2σc1−α, then accept the null hypothesis H01 and reject H0k1 , . . . , H02,
and stop the testing procedure;
else then reject H0k1 , H0k1−1 . . . , H01 and stop the testing procedure.
Here c1−α is the critical value derived in section 3.4 by taking into consideration the
adaptive design, and k1 is the number of dose groups fully enrolled.
3.6 APPLICATION OF THE MODIFIED STEPDOWN TESTING
PROCEDURE IN ADAPTIVE DOSE STUDY WITH A BINARY
ENDPOINT
As discussed in the previous chapter, the outcome in clinical studies is often expressed as a
binary variable. Usually we can use the approaches of adaptive design and stepdown testing
based on normal distribution theory as long as the sample size is moderate or large, and the
expected proportion is not very close to 0 or 1. However, in an adaptive study with small to
moderate sample size, the sample size at the first stage is usually small, and thus cut points
specified based on the continuous normal approximation of testing statistics usually can not
be achieved. The cut point is often defined in terms of the number of events instead. In a
comparative dose study, the cut points are most conveniently specified as the difference in
the number of events between the control group and the dose groups. A cut point specified in
this way does not always define a unique cut point when some relative drug efficacy measure
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is used. For example, suppose at dose level di, odds ratio
pi×(1−p0)
(1−pi)×p0 is defined as the drug
effect variable. Use the same notation of sample sizes ni, ni1, n0 and n01 as before, and write
the number of event observed in dose i group and the control group at the first stage as
mi1 and m01 correspondingly, and the critical point for mi1 −m01 is Mi. The corresponding
critical value λi for odds ratio observed at the first stage is
λi =
mi1 × (n01 −m01)
(ni1 −mi1)×m01
=
(m01 +Mi)× (n01 −m01)
(ni1 − (m01 +Mi))×m01
= g(m01,Mi),
Hence λi is a function of bothMi and m01, and the cut pointMi does not uniquely define
the cut point for the odds ratio. Although the actual corresponding odds ratio cut point can
be calculated at the time of testing, the conditional distribution of the observed overall odds
ratio can not be derived based on it. The same kind of difficulty will be encountered if the
relative risk pi/p0 or difference of arcsin square-root of proportions, arcsin p
1
2
i − arcsin p
1
2
0 are
used as the drug effect variables. We will propose an approach to deal with this difficulty
by using an approximate mixture normal distribution for the odds ratio. The result can be
easily applied to relative risk and other similar measurements with minor modifications.
3.6.1 Expected conditional distribution approach for stepdown testing in clin-
ical study with binary outcome
Using the above notation, if at dose level di the critical value for adaptive sampling isMi, then
the corresponding critical value for odds ratio can be expressed as λi =
(m01+Mi)×(n01−m01)
(ni1−(m01+Mi))×m01 .
Under the null hypothesis, the numbers (m01) of event in control group and the number
(mi1) of event in dose group i have binomial distributions with common probability p and
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sample sizes n01 and ni1. Let set Ui be all the possible values of the odds ratio given sample
sizes n01 and ni1 and difference in number of events Mi. For any value ω ∈ Ui, write the set
of m01 as Vω = {m : Max(0, −Mi) 6 m 6 Min(n01, ni1 −Mi) and (m+Mi)×(n01−m)(ni1−(m+Mi))×m = ω}.
When m01 ∈ Vω, we have
mi1 −m01 >Mi ⇐⇒ (m01 +Mi)× (n01 −m01)
(ni1 − (m01 +Mi))×m01 > ω
Therefore the probability of the discrete distribution of the critical value in terms of odds
ratio can be evaluated as
Pr(λi = ω) = Pr {m01 ∈ Vω}
=
1
Gp
∑
m∈Vω
(
n01
m
)
pm(1− p)n01−m, (3.3)
where
Gp =
Min(n01,ni1−Mi)∑
m=Max(0,−Mi)
(
n01
m
)
pm(1− p)n01−m (3.4)
Since p is usually unknown, the estimate pˆ = (m0 +mi)/(n0 + ni) can be plugged into the
equation, wherem0,n0,mi and ni represent the total number of events and subjects in control
group and dose group i. Thus, approximately,
Pr(λi = ω) =
1
Gpˆ
∑
m∈Vω
(
n01
m
)
pˆm(1− pˆ)n01−m (3.5)
Under the null hypothesis, the log odds ratio zi1 = log(oddi1) has the approximate normal
distribution N(0, σ˜2), where σ˜2 = 1
m01
+ 1
n01−m01 +
1
mi1
+ 1
ni1−mi1 . And zi = log(oddi) has
the approximate normal distribution N(0, σ2), where σ2 = 1
m0
+ 1
n0−m0 +
1
mi
+ 1
ni−mi . The
marginal distribution of the test statistics
zi = log(oddi) = log
(
mi × (n0 −mi)
(ni −mi)×m0
)
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can be obtained by the following expected conditional distribution:
f(zi|mi1 −m0i >Mi)
=
∑
ω∈Ui
Pr {λi = ω}f(zi|zi1 > log(λi))
And the critical value c1−α for level α hypothesis testing of drug effect at dose group i
can be obtained by solving the following:
Pr(mi1 −m01 >Mi and zi > C)
= Pr(mi1 −m01 >Mi)× Pr(zi > C|mi1 −m01 >Mi)
= α
Under the null hypothesis Hi, the above probabilities can be expressed separately as:
Pr(zi > C|mi1 −m01 >Mi)
=
∑
ω∈Ui
Pr(λi = ω)
∫ +∞
log(ω)
fzi1(w)
1∫ +∞
log(ω)
fzi1(v)dv
∫ c1−α
−∞
fzi|zi1=w(z)dzdw
and
Pr(mi1 −m01 >Mi)
=
Min(n01,ni1−Mi)∑
m01=0
ni1∑
mi1=Max(0,m01+Mi)
{
(
n01
m01
)
pm01(1− p)n01−m01
×
(
ni1
mi1
)
pmi1(1− p)ni1−(mi1)}
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The probability density function fzi|zi1(z) of the conditional distribution of zi can be
easily obtained since the covariance between zi and zi1 is known to be approximately equal
to σ2.
3.6.2 A Monte Carlo Simulation Approach to Obtain the Critical Values
Solving for the critical values of testing statistics zi involves a double integral of the condi-
tional distribution:
∫ +∞
log(ω)
fzi1(w)
1∫ +∞
log(ω)
fzi1(v)dv
∫ c1−α
−∞
fzi|zi1=w(z)dzdw
A closed mathematical form of the density function is unavailable. However, we can use
Monte Carlo simulation approach to generate a sufficiently large sample from the marginal
distribution of zi, and estimate the desired percentage point from the empirical distribution.
We propose to use a Monte Carlo Composition [30] with Rejective/Acceptance method for
our problem. The simulation can be performed in the following three steps to sample from
the marginal distribution fzi(z):
1. Draw ω∗ from pm(ω)
2. Draw y∗ from fzi1(y)
3. If y∗ > ω∗, then keep y∗ and go to step 4. Else then go back to step 2
4. Draw z∗ from fzi|y∗(z)
The point (ω∗, y∗, z∗) is an observation from the joint distribution, while z∗ is an ob-
servation from the marginal fzi . The SAS macro program I wrote to perform the above
simulations only needs about 3 to 5 minutes in an artificial trial to compute all the critical
values for each of the possible adaptive designs.
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3.6.2.1 Example The following example of a clinical dose study is used to illustrate the
steptest procedure that incorporates adaptive design. Suppose in an adaptive clinical dose
trial the treatment outcome is a binomial random variable, which indicates the number of
treatment successes. An experimental drug is studied at multiple dose levels for its effect on
increasing the success rate. An active control treatment is used, and the drug effect at each
dose group is measured as odds ratio relative to the control group. From past data, patients
who received the control treatment have been observed to have a 10% success rate following
the treatment. The dose study is designed such that 150 patients are enrolled in each of the
dose groups and the control group at the first stage. If after the first stage, the number of
patients having the adverse outcome at any dose group is no more than that in the control
group minus a certain pre-specified number δ (δ is an integer but could be negative or zero),
then at the second stage 350 more subjects will be enrolled into each dose group and the
control group.
After completion of the second stage, data from the dose groups that have been fully
enrolled will be analyzed for potential drug efficacy. If the dose response can be reasonably
assumed to be isotonic, i.e., the drug at higher dose levels is at least as effective as the
lower doses, finding the lowest effective dose level is usually desired and a stepdown testing
procedure is the most widely used approach. The natural logarithm of the odds ratio is used
as the testing statistic and is assumed to be normally distributed. However, the critical value
for test statistics at each step has to be adjusted for the adapative sampling. Table 3.1-3.3
list the one-sided critical values to be used for the test. These critical values are calculated
using the Monte Carlo Composition [30] with Rejective/Acceptance method. We assume
that the treatment success rate is 10% in the control group, and the treatment success rate
is 15% when calculating the power of the test.
The simulation results indicate that the actual Type I error probability for the log odds
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Table 8: Adjusted Critical Values for One-sided Test with α=0.1
δ for Probability of Critical Value Simulated Adjusted Unadjusted
Adaptive 2nd Stage for Log of Type I Error Power Power
Design Under H0 Odds Ratio Probability
-8 0.94936 0.26718 0.10351 0.84147 0.83745
-7 0.92599 0.26685 0.10268 0.84186 0.83777
-6 0.89510 0.26509 0.10437 0.84345 0.83651
-5 0.85578 0.26577 0.10221 0.84174 0.83560
-4 0.80752 0.26404 0.10370 0.83995 0.83154
-3 0.75044 0.26351 0.10252 0.83682 0.82866
-2 0.68540 0.26216 0.10234 0.83127 0.82131
-1 0.61399 0.26049 0.09965 0.82240 0.81188
0 0.53847 0.25553 0.09865 0.81404 0.79839
1 0.46153 0.24789 0.09898 0.80172 0.78074
2 0.38601 0.23526 0.09909 0.78525 0.75592
3 0.31460 0.21705 0.09872 0.76048 0.72453
4 0.24956 0.18938 0.10138 0.72816 0.68491
5 0.19248 0.14802 0.10176 0.68632 0.63985
Pnull = 0.1 pa = 0.15 n1 = 150 n2 = 350
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Table 9: Adjusted Critical Values for One-sided Test with α=0.05
δ for Probability of Critical Value Simulated Adjusted Unadjusted
Adaptive 2nd Stage for Log of Type I Error Power Power
Design Under H0 Odds Ratio Probability
-8 0.94936 0.34493 0.052680 0.72500 0.72285
-7 0.92599 0.34351 0.052610 0.72834 0.72338
-6 0.89510 0.34167 0.054145 0.73024 0.72230
-5 0.85578 0.34284 0.052045 0.72729 0.72230
-4 0.80752 0.34119 0.053775 0.72722 0.71933
-3 0.75044 0.34164 0.053080 0.72560 0.71749
-2 0.68540 0.34080 0.053180 0.72064 0.71261
-1 0.61399 0.34108 0.050935 0.71483 0.70699
0 0.53847 0.33896 0.050020 0.70802 0.69719
1 0.46153 0.33400 0.050495 0.70221 0.68482
2 0.38601 0.32659 0.050110 0.69228 0.66633
3 0.31460 0.31527 0.050510 0.68009 0.64285
4 0.24956 0.29924 0.051105 0.66015 0.61170
5 0.19248 0.27558 0.050385 0.63656 0.57675
Pnull = 0.1 pa = 0.15 n1 = 150 n2 = 350
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Table 10: Adjusted Critical Values for One-sided Test with α=0.025
δ for Probability of Critical Value Simulated Adjusted Unadjusted
Adaptive 2nd Stage for Log of Type I Error Power Power
Design Under H0 Odds Ratio Probability
-8 0.94936 0.41194 0.026690 0.59685 0.59685
-7 0.92599 0.41048 0.027710 0.59985 0.59670
-6 0.89510 0.40903 0.027700 0.60472 0.59539
-5 0.85578 0.41005 0.027400 0.60212 0.59607
-4 0.80752 0.40953 0.027420 0.60000 0.59411
-3 0.75044 0.41116 0.027300 0.59722 0.59412
-2 0.68540 0.41078 0.026935 0.59353 0.59037
-1 0.61399 0.41111 0.025995 0.58987 0.58691
0 0.53847 0.41057 0.025200 0.58307 0.58020
1 0.46153 0.40717 0.025480 0.58236 0.57161
2 0.38601 0.40201 0.025650 0.57799 0.55990
3 0.31460 0.39422 0.025560 0.57610 0.54350
4 0.24956 0.38172 0.026200 0.56595 0.52147
5 0.19248 0.36618 0.026420 0.55490 0.49586
Pnull = 0.1 pa = 0.15 n1 = 150 n2 = 350
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ratio using normal approximation is very close to the nominal level in a clinical study with
sample size of a typical Phase II trial. The corresponding power under the alternative hy-
pothesis and the probability of subjects at second stage being saved under the null hypothesis
can be easily calculated, and these numbers can be used for choosing the best design when
the appropriate criteria are given.
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4.0 OPTIMAL STAGE-WISE ADAPTIVE CLINICAL DOSE STUDY
DESIGN
4.1 INTRODUCTION
Sequential clinical study designs consist of one or more interim analyses/comparisons in
addition to the final analysis/comparison at the end of the study. The study can be stopped
if the treatment is found to be inferior or superior to the control at any interim analysis. The
use of sequential design is motivated by both the ethical consideration to assign more patients
to the effective treatment as soon as possible, and by the economical need to reach the reliable
conclusion with the minimum resources. Extensive discussions on various approaches to
design sequential studies as well as the theoretical background are available in the books by
Jennison and Turnbull [13](2000) and Whitehead [33](1997).
Sequential designs have been widely studied and used in Phase II clinical study involving
treatment selection or treatment screening. In drug development process, usually the toxicity
and/or tolerability is studied in Phase I study. If the toxicity level is acceptable, potential
efficacy is studied in Phase II trials to determine whether a confirmatory Phase III trial,
which is often large-scale and very costly, should be conducted. Phase II trial that involves
dose response study has become increasingly common, and the parallel multiple dose study
is one of the typical Phase II dose designs.
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The results of a Phase II drug study often show that a drug candidate believed to be
promising lacks sufficient efficacy to warrant further Phase III confirmatory trial. ”Futility
analysis”, which refers to the interim analysis that assesses the probability of the drug being
found promising, enables us to stop the study early and allocate the saved resources to more
promising studies. In a multi-dose Phase II trial, futility analysis can be conducted at each
dose level so that we can allocate more resources to more promising dose groups.
4.2 LITERATURE REVIEW ON ADAPTIVE PHASE II CLINICAL
STUDY DESIGNS
Simon [23](1989) proposed an approach to design the optimal two-stage single-arm phase II
study. It allows the study to stop after the first stage if there is no sufficient evidence of
drug activity. Minimum expected sample size and/or minimum maximum sample size are
used to choose the optimal design. Chen [7] (1997) proposed the extension of the design
to three-stage. Hanfelt [11](1999) extended Simon’s design to phase II studies where choice
of dosage is not clear. Hanfelt’s design has two stages at each dose, and permits one dose
escalation if the drug effect can’t be verified after first and/or second stage of the initial
dose. Different optimization criteria are discussed, including expected sample size, median
or mode sample size, and minimum maximum sample size.
Feder et al [10](1991) discussed a two-stage adaptive dose allocation optimal design for
parametric dose response estimation. At the first stage, subjects are allocated to dose levels
such that the parameters can be best estimated based on the prior assumption. At the
second stage, the data from the first stage are used to update the function form and the
subjects allocation is modified accordingly.
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Thall [31][32](1988 and 1989) studied a two-stage design with binary outcome that se-
lects the best treatment at the first stage, and conduct the second stage study only on the
selected treatment if the observed treatment effect crosses some pre-specified boundary in
first stage. He proposed to use two quantities, marginal improvement δ1, and significant im-
provement δ2 to derive the Least Favorable Configuration (LFC), and to calculate the power
and Type I error probability based on LFC. The optimal design is obtained to minimize
the weighted average of the sample sizes of the two stages of study. Schaid, Wieand and
Therneau [21](1990) proposed a similar design when the endpoint variable is a survival time.
Stallard [26](2003) extended the work by Thall and Schaid by using the efficiency score as
the test statistic, and incorporating sequential design in studying the single experimental
treatment at the second stage after the best treatment has been selected at the first stage.
Leung [16](2001) incorporated the usually assumed monotone relationship between toxi-
city and dosage into the design. He suggested a sequential dose finding study that performs
isotonic regression after each stage of the study, and uses the isotonic regression estimate of
the drug effect as a test statistic to decide whether to stop the study or to continue to the
next dose level.
Pallay [20](2001) discussed a Phase II two-dose futility study using a decision analytic
approach. Two-stage sequential design is used at each dose. Cost and gain functions are
pre-specified and the study design is optimized based on the eventual profit of the drug
development. Stallard [27] [26] (1998 and 2003) proposed to use decision-theoretic design
based on more general gain function of drug effect and subjects allocation. The opportunity
cost of not6 spending resources on other competing treatments is also considered.
Previous studies of adaptive design for Phase II clinical trial have been limited to one or
more of the following areas, therefore can not be readily applied to the kind of Phase II dose
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study we have described: 1. Frequently, usually in early stage toxicity study, parametric
dose response estimation is desired. In those cases, the optimal design is aimed to achieve
the minimum variance in parameter estimation(s). 2. In a Phase II study when multiple
treatments are compared to a control group to select potentially effective treatment(s) to
enter a Phase III study, the monotone assumption of effect exists in dose study either does
not exist or is not taken in consideration into the study design. 3. Usually only a continuous
response with a normal distribution is considered. In case of binary or categorical responses,
certain types of normal approximation and/or data transformation are used without validity
and sensitivity analysis. 4. Most study designs simply use the minimum expected sample
size or min-max sample size as the optimization criteria. However, sometimes the total
resources to be expended has already been decided and efficiency of resource allocation is
the study design objective. 5. Extensive research has been concentrated on Phase II cancer
study, where the tumor reduction probability is examined to assess the potential therapeutic
effect of new chemical compounds. Therefore, the studies are singled-armed and are not
comparative in nature.
In practical clinical studies, the study process and design are in general constrained by
scientific and clinical considerations and operation logistics. A general statistically optimal
design doesn’t always find its way into the application. In this chapter we will propose a
study design that satisfies the constraints of certain type of dose escalation studies and also
achieves the maximum statistical efficiency under the study constraints.
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4.3 AN ADAPTIVE STUDY DESIGN FOR DOSE ESCALATION STUDY
The study design we will discuss here is aimed to achieve optimal efficiency for a comparative
dose escalation Phase II clinical study similar to the cardiovascular clinical study mentioned
in the first chapter. Such a dose escalation study is commonly used in clinical studies
involving severe medical conditions. The efficacy of the drug is often measured using a
binary variable that indicates the treatment success of the target disease or the occurrence
of the target adverse outcome. Usually two to six pre-specified dose levels of the experimental
drug are studied and isotonic dose response can be assumed. An active control arm that uses
the standard treatment is used, and the drug effect is measured by a relative measurement
such as difference of proportions, relative risk or odds ratio.
4.3.1 Proposed Study Design
Suppose there are k dose levels, d1, d2, . . . , dk, and an active control arm d0, and the measure
of drug effect at the control group and each dose level is normally distributed with the same
known variance σ2, and with means µ0, µ1, . . . , µk, respectively. The study starts from the
lowest dose level, and escalates to the second lowest dose level after the study enrollment
in the lowest doses is finished and study data has been collected and analyzed. The study
continues in this way until the highest dose level is studied, or the study is terminated due
to safety concerns. To keep the treatment allocation blinded and also the control population
comparable, the subjects in the control arm are continuously enrolled along with subjects
to be allocated to each dose level. Randomization by block is used to maintain the desired
ratio of the numbers of subjects between control and treatment.
I propose to use a two-stage adaptive enrollment design at each dose step. The enrollment
design is aimed to use the subjects more efficiently by performing a futility assessment after
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the first stage enrollment, and skipping the second stage enrollment if the observed drug
effect of the dose group is smaller than a pre-specified cut point. The saved second stage
subjects of the abandoned dose group are then equally allocated to the remaining higher-
dose groups. The number of subjects at first stage enrollment is the same at every dose step.
Suppose at a dose step, say dose i, the observed drug effect after the first stage enrollment is
larger than the cut point λi, then the second stage enrollment will proceed. After the dose
step i is completed, all the higher dose level will be fully enrolled without first stage futility
assessment.
Suppose the total planned number of subjects for k dose groups and the control group is
N . At the first stage enrollment of each dose step only n1 (n1 <
N
k+1
) subjects are enrolled.
I propose the following subject allocation scheme which ensures that the control group and
all the dose groups that pass the first stage screen have the same number of subjects. Also
suppose that after the first stage of the adaptive enrollment, the drug effect for the control
group and dose group i, i = 1, 2, . . . , k, is estimated using the observed sample means x¯0i
and x¯i1 respectively. Write the cut point at dose group i as λi. The dose escalation study
starts from the lowest dose group:
1. Enroll n1 subjects in the lowest dose group and
N
2k(k+1)
subjects in the control group.
Calculate the drug effect estimate in the control group and the lowest dose group, x¯01
and x¯11.
• If x¯11− x¯01 6 λ1 then stop enrollment for the lowest dose group and go to the second
lowest dose group (Step 2).
• Else if x¯11 − x¯01 > λ1, then enroll additional Nk+1 − n1 subjects to the lowest dose
group, and additional N
2k(k+1)
subject to the control group. In each of the higher
dose steps, enroll N
k+1
and N
k(k+1)
subjects to the dose group and the control group,
respectively. (Study enrollment finished)
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2. Enroll n1 subjects in the second lowest dose group, and
N−n1
2k(k−1) − N2k(k+1) subjects in the
control group. Calculate the drug effect estimate in the control group (use all data) and
the second lowest dose group, x¯02 and x¯21.
• If x¯21 − x¯02 6 λ2 then stop enrollment for the second lowest dose group and go to
the third lowest dose group (Step 3).
• Else if x¯21− x¯02 > λ2, then enroll additional N−n1k −n1 subjects to the second lowest
dose group, and additional N−n1
2k(k−1) subject to the control group. In each of the higher
dose steps, enroll N−n1
k
and N−n1
k(k−1) subjects to the dose group and the control group,
respectively. (Study enrollment finished)
· · · · · ·
I. Enroll n1 subjects in dose group i, and
N−(i−1)n1
2(k−i+1)(k−i+2) − N−(i−2)n12(k−i+2)(k−i+3) subject in the
control group. Calculate the drug effect estimate in the control group (use all the data
collected in the control group) and the second highest dose group, x¯0i and x¯i1.
• If x¯i1 − x¯0i 6 λi then stop enrollment for dose group i and go to dose group i+ 1.
• Else if x¯i1 − x¯0i > λi, then enroll additional N−(i−1)n1k−i+1 − n1 subjects to dose group i,
and additional N−(i−1)n1
2(k−i+1)(k−i+2) subject to the control group. In the highest dose step,
enroll N−(i−1)n1
k−i+1 and
N−(i−1)n1
(k−i+1)(k−i+2) subjects to the dose group and the control group,
respectively. (Study enrollment finished)
· · · · · ·
K. In the highest dose step, enroll N−(k−1)n1
2
and N−(k−1)n1
2
− N−(k−2)n1
12
subjects to the dose
group and the control group, respectively. (Study enrollment finished)
Dose groups that stop enrollment after the first stage are considered not having sufficient
evidence of efficacy to be further studied. Suppose at dose level dj, we observed that x¯j1 −
x¯0j > λj for the first time, and therefore enroll the remaining subjects such that the control
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group and the dose groups at or above dose level j have the same sample size. The final
estimates of drug effect for all the dose groups at or above dose level dj are correlated with
x¯j1 − x¯0j because they use the common control group. Since the distribution of x¯j1 − x¯0j is
truncated by the adaptive sampling procedure, the marginal distributions of the drug effect
estimates for all the higher dose group are all biased. Therefore the statistical inferences we
use to analyze the study data need to be adjusted.
I will describe the stepdown testing procedure that incorporates the adaptive enrollment
in a three-dose dose escalation study. Write the drug effect estimate for dose group i as
x¯i − x¯0, i = 1, 2 or 3. Also write the event that the null hypothesis Hi0 : µi − µ0 6 0 is
rejected when Hi0 is in fact true as Si, i.e., Si is the event the a Type I error occurs in the
testing procedure at dose level i. When i = 1:
Prob(S1)
= Prob(x¯1 − x¯0 > C1 and x¯11 − x¯01 > λ1|µ1 6 µ0)
6 Prob(x¯1 − x¯0 > C1 and x¯11 − x¯01 > λ1|µ1 = µ0)
= Prob(x¯1 − x¯0 > C1|x¯11 − x¯01 > λ1 , µ1 = µ0)× Prob(x¯11 − x¯01 > λ1|µ1 = µ0)
Therefore the derivation of the critical value C1 is reduced to the problem we have discussed
in chapter 3 (3.1) by setting the last probability to α and solving for C1. When i = 2, the
event S2 can be expressed as:
S2 = {x¯11 − x¯01 6 λ1, x¯21 − x¯02 6 λ2, x¯2 − x¯0 > C21 | µ2 6 µ0}⋃
{x¯11 − x¯01 > λ1, x¯2 − x¯0 > C22 | µ2 6 µ0}
Since the two subsets of S2 are mutually exclusive, we have
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Prob(S2) = Prob(x¯11 − x¯01 6 λ1, x¯21 − x¯02 6 λ2, x¯2 − x¯0 > C21 | µ2 6 µ0)
+ Prob(x¯11 − x¯01 > λ1, x¯2 − x¯0 > C22 | µ2 6 µ0)
6 Prob(x¯21 − x¯02 > λ2, x¯2 − x¯0 > C21 | µ2 = µ0)
+ Prob(x¯11 − x¯01 > λ1, x¯2 − x¯0 > C22 | µ2 = µ1 = µ0)
= Prob(x¯2 − x¯0 > C21|x¯21 − x¯02 > λ2 , µ2 = µ0)× Prob(x¯21 − x¯02 > λ2|µ2 = µ0)
+ Prob(x¯2 − x¯0 > C22|x¯11 − x¯01 > λ1 , µ1 = µ2 = µ0)
×Prob(x¯11 − x¯01 > λ1|µ1 = µ0)
I propose to use the Bonferroni method to assign Type error rate α
2
to each of the two
probabilities at the last step of above inequality. Again the critical values C21 and C22 can
be solved by using the simulation approach I proposed in Chapter 3. Under the proposed
study design, the testing at the highest dose level (dose 3) is always performed irrespective
of the results of futility assessments at early dose steps. Although the results of the futility
assessments affect the sample size of the dose effect estimates at dose level 3, the correlation
between x¯3 − x¯0 and the first stage estimates at earlier dose levels, x¯11 − x¯01 and x¯21 − x¯02,
is usually small. This is easy to understand since the only common data used is the first
stage data in the control group, which is usually a fraction of the sample size at the last
dose group. Therefore I propose to use 1√
2/n
σZα as the critical value of the testing at dose
level 3, which is essential the usual Z-test. Here Zα is the α percentile of standard normal
distribution, σ is the common standard deviation of drug response, and n is the final sample
size in the control group and each dose group that is fully enrolled. The simulation study I
performed shows that the actual Type I error is very close the nominal level α.
When inference on simultaneous confidence intervals (SCI) is desired, the modified max-
min procedure can be used to derive the simultaneous conference intervals of the correlated
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dose effects, and a similar adjustment for the adaptive enrollment at dose i can be made.
The modification for adaptive enrollment using SCI will be discussed later in this chapter.
The modified stepdown testing procedure or the one-sided modified simultaneous confi-
dence intervals approach to find the effective dose levels are the two approaches most widely
used to analyze comparative multi-dose study. I propose a stage-wise optimization method
to obtain the cut points for adaptive sampling at each dose level when these two analysis
approaches are used. However, the optimization method can also be applied when other
analysis approaches are used or these two analysis approaches are modified.
4.3.2 Optimal Adaptive Design When Stepdown Testing Procedure is Used to
Analyze the Study Data
The goal of using the cut points to assess the drug futility in this adaptive design is to
make the best decision on whether the second stage enrollment at a dose step should be
proceeded based on the observed drug effect from the first stage data. In order to discuss
the optimization approach to decide these cut points, I’ll first define the design criteria that
I will use to evaluate different cut points.
In a Phase II dose study, one desired property of a study design is to detect the effective-
ness of the experimental drug with as much power as possible, which is also the objective
of any Phase II clinical study. In a dose study, if the efficacy exists at multiple dose levels,
we also wish to identify the lowest effective dose level that is studied. These two competing
objectives require somewhat different subject allocation strategies. To have good power to
detect the effectiveness of a experimental drug, we should assign as many subjects to the
highest dose level as possible, since the highest dose level is the most effective under isotonic
dose response assumption. On the other hand, to identify the lowest effective dose level, we
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need to assign more subjects to all of the effective dose groups. Average power to detect all
the effective dose groups is often used as one of the criteria to evaluate the performance of
dose study analysis approaches. Tamhane [29] used this criteria along with other quantities
to compare the efficiency of various step testing procedures to analyze dose study data. In
order to choose the study design that achieves the optimal balance between the two objec-
tives of a dose study, we propose to use a weighted average power to find all the effective dose
groups as the study design criteria. Suppose we have k dose levels d1, d2, . . . , dk, r effective
dose levels dk−r+1, dk−r+2, . . . , dk. Write the event that dose i(k − r + 1 6 i 6 k) and all
higher dose levels being identified to be effective as Ii, for a specific study design, the design
criteria Gr is defined as
Gr =
k∑
i=k−r+1
γiPr(Ii|s) /
k∑
i=k−r+1
γi , γk−r+1 > γk−r+2 > . . . > γk
The relative values of γi’s should be decided based on the nature of the therapeutic area
studied by the dose study and the corresponding study goal. Specifically, γ1 = γ2 = . . . = γk
is used in cases where the target disease is extremely severe and there is no alternative
effective treatment. In such cases, the goal is to identify the tolerable effective dose level as
soon as possible, and identifying lower effective dose levels provides little additional benefit
as long as some higher effective dose level(s) can be identified. On the other hand, weights
γ1, γ2, . . . , γk that reflect steep decrease in Gs when the number of identified effective dose
levels decreases can be used in cases where the degree of effectiveness is less important,
and higher doses often involve serious side effects, difficulty in administration and/or much
higher cost. In these cases, finding the lowest effective dose level is the most important
objective. Appropriate selection of γi’s can achieve the desired balance when both objectives
are important.
I assume that the drug response variables in the control group and each dose group
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are normally distributed, with means of the distributions as µ0, µ1, . . . , µk correspondingly.
The dose level i is defined to be effective if µi > µ0, and ineffective otherwise. Let δ
be the smallest meaningful drug effect that is measured as the difference between drug
responses of the control group and each of the dose groups, and we will be interested in the
power of the analysis procedure to detect the dose levels that have drug effect higher than
δ (µi > µ0 + δ). The use of smallest meaningful effect δ is also statistically useful since the
power to distinguish between effective and ineffective dose levels can not be analyzed if µi
and µ0 are allowed to be arbitrarily close to each other [31].
4.3.2.1 A Conservative Stage-Wise Optimization Approach Under Least Favor-
able Configurations Optimization of study design parameters are usually achieved under
a set of possible drug effect configurations. For example, Simon [23], Hanfelt [11] and Chen
[7] provided the optimal cut points for their adaptive designs under a list of possible drug
effect configurations in the treatment group and/or the control group. However, in a Phase
II study with multiple dose groups, the dose response of the experimental drug is usually
not clear, and it is unrealistic to specify a set of possible drug effects at each dose with any
confidence. Thall [31] [32] in his proposed adaptive 2-stage design derived the optimal cut
points under the least favorable configuration (LFC). The LFC in Thall’s study design is the
drug effect configuration under which the overall power to find the effective drug group(s)
achieves the minimal. This is justified by the fact that in a well studied therapeutic area
in treating serious diseases, one usually expects the improvement of treatment effect of any
experimental medicine over the standard therapy to be only marginal, if any.
I propose to use a conservative stepwise optimization approach for the adaptive study
design here. The least favorable configurations are defined at each dose step such that the
probability of making the unfavorable enrollment decision is the highest, and the weighted
60
average power to find all effective dose groups is the smallest. Suppose the study is at dose
step i, and we have the observed treatment effect after the first stage enrollment x¯i1 − x¯0i.
The unfavorable enrollment decision is made if we observe x¯i1−x¯0i > λi when in fact µi 6 µ0,
or if we observe x¯i1 − x¯0i 6 λi when in fact µi > µ0 + δ. I define the opportunity loss of
using the adaptive design as the decrease in weighted average power when the unfavorable
enrollment decision is made. The optimal value of the cut point λi is derived such that under
least favorable configurations the maximum opportunity loss achieves its minimum.
Define the following two dose response configurations at dose step i, i = 1, 2, . . . , k − 1,
• LFCi1: µk = µk−1 = . . . = µi+1 = µ0 + δ; µi = µ0
• LFCi2: µi = µi+1 = . . . = µk = µ0 + δ
I’ll prove as following that under each of the two dose response configurations at dose
i, the probability of making a unfavorable enrollment decision after the interim look is the
biggest, while in the same time the expected weighted average power is the smallest.
Proposition 4.3.1. Suppose the drug responses have the normal distributions as described
earlier in this Chapter. At dose level i, i = 1, 2, . . . , k − 1, define
pi1 = Prob(x¯i1 − x¯0i > λi | µi 6 µ0)
pi2 = Prob(x¯i1 − x¯0i 6 λi | µi > µ0 + δ)
1. pi1 or pi2 achieves the maximum under LFC1 or LFC2, correspondingly.
2. The weighted average power to identify all effective dose levels (G) achieves its minimum
under LFC1 or LFC2, correspondingly.
Proof.
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1.
pi1 = Prob(x¯i1 − x¯01 > λi | µi 6 µ0)
= Prob(
(x¯i1 − x¯01)− (µi − µ0)√
σ2/ni1 + σ2/n01
>
λi − (µi − µ0)√
σ2/ni1 + σ2/n01
| µi 6 µ0)
= Prob(Z >
λi − (µi − µ0)√
σ2/ni1 + σ2/n01
| µi 6 µ0) (Z ∼ N(0, 1))
6 Prob(Z > λi − (µi − µ0)√
σ2/ni1 + σ2/n01
| µi = µ0)
= Φ(
λi√
σ2/ni1 + σ2/n01
)
Similarly, we can also show that
pi2 = Prob(x¯i1 − x¯01 6 λi | µi > µ0 + δ)
= Prob(
(x¯i1 − x¯01)− (µi − µ0)√
σ2/ni1 + σ2/n01
6 λi − (µi − µ0)√
σ2/ni1 + σ2/n01
| µi > µ0 + δ)
= Prob(Z 6 λi − (µi − µ0)√
σ2/ni1 + σ2/n01
| µi > µ0 + δ)
6 Prob(Z 6 λi − (µi − µ0)√
σ2/ni1 + σ2/n01
| µi = µ0 + δ)
= 1− Φ( λi − δ√
σ2/ni1 + σ2/n01
)
2. Suppose there are r effective dose levels. By the assumption of isotonic dose response,
we have the effective dose groups as k− r+1, k− r+2, . . . , k. When a stepdown testing
procedure is used to identify the effective dose levels, we have
Gr =
k∑
i=k−r+1
γiPr(Ii) /
k∑
i=k−r+1
γi
=
k∑
i=k−r+1
γiPr(Reject Hk0, Hk−1 0, . . . , Hi0 | µk > . . . > µi > µ0 + δ) /
k∑
i=k−r+1
γi
>
k∑
i=k−r+1
γiPr(Reject Hk0, Hk−1 0, . . . , Hi0) | µk = . . . = µi = µ0 + δ) /
k∑
i=k−r+1
γi
(4.1)
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Since Pr(Ii) 6 Pr(Ii) 6 . . . 6 Pr(Ik), it is obvious that for, any given sampling scheme,
Gr achieves the minimum when the number of effective groups r is as large as possible.
Under any given drug effect configuration, the weighted expected power is a function of
the cut point λi. At dose level i, write the opportunity loss under LFC
i
1 and LFC
i
2 as L
i
1
and Li2 respectively, they can be expressed as:
Li1 = Gk−i(No 2nd Stage Enrollment | LFCi1) − Gk−i(λi | LFCi1)
Li2 = Gk−i+1(Full Enrollment | LFCi2) − Gk−i+1(λi | LFCi2)
Li(λi) = max(L
i
1, L
i
2)
The weighted average power Gk−i(No 2nd Stage Enrollemnt | LFC1) is equivalent to
setting the cut point λi at +∞ when the dose response configuration is under LFCi1, and
the weighted average power Gk−i+1(Full Enrollment | LFCi2) is equivalent to setting the
cut point λi at −∞ when the dose response configuration is under LFCi2. The optimal cut
point λi is chosen such that the maximum opportunity loss Li at dose step di achieves the
minimum. As the dose step moves up, the sample size available increases and the number
of dose groups higher than the dose step decreases. The optimization procedure is then
performed at each dose step to derive the cut points for the adaptive design.
4.3.2.2 A Back-Induction Algorithm to Solve for the Optimal Cut Points If
after the first stage enrollment of dose step i, i = 1, 2, . . . , k − 1, we observe x¯i1 − x¯0i > λi,
then the second stage enrollment will be proceeded, and all the higher dose group will be
enrolled with the same sample size. The weighted average power for finding the effective
dose groups under a given dose response configuration can be calculated. However, we
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observe x¯i1 − x¯0i 6 λi, the study escalates to dose step i + 1, and adaptive enrollment
will be implemented again. The calculation of the weighted average power of the study
then will involve the cut point λi+1. Actually, the cut points for all the higher dose steps
λi+1, λi+2, . . . , λk−1 need to be known to calculate the weighted average power. Therefore, I
propose to use a back-induction algorithm to derive the optimal cut points λ1, λ2, . . . , λk−1
for the adaptive dose escalation study.
I will derive the proposed back-induction optimization algorithm in a dose escalation
study with three dose groups. Suppose the total sample size for the dose study is N , and
sample size for the first stage enrollment at each dose step is n1. Using the treatment
allocation scheme presented previously in the chapter, the sample size of each treatment
group under different enrollment decision can be expressed as:
• x¯11 − x¯01 < λ1 and x¯21 − x¯02 < λ2: N3 = (N − 2n1)/2
• x¯11 − x¯01 < λ1 and x¯21 − x¯02 > λ2: N2 = (N − n1)/3
• x¯11 − x¯01 > λ1: N1 = N/3
Write the event that lowest effective dose level 1, 2 or 3 is identified using the stepdown
testing procedure as I1, I2 and I3, correspondingly, and the weights of the weighted average
power are γ1, γ2 and γ3. The optimal cut points are derived using the 2-step procedure:
1. Suppose x¯11 − x¯01 < λ1 is observed, therefore the second stage enrollment of dose step
1 is skipped. Observed drug effect of dose level 2 after the first stage enrollment is
x¯21− x¯02. Using cut point λ, the expected weighted average power under LFC21 (µ2 = µ0
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and µ3 = µ0 + δ) and LFC
2
2 (µ2 = µ3 = µ0 + δ) can be calculated as
E(G21|λ) = Prob(x¯21 − x¯02 > λ | µ2 = µ0)× Prob(I3|N2)
+Prob(x¯21 − x¯02 < λ | µ2 = µ0)× Prob(I3|N3)
E(G22|λ) = Prob(x¯21 − x¯02 > λ | µ2 = µ0 + δ)
×(γ2Prob(I2|N2) + γ3Prob(I3|N2))/(γ2 + γ3)
+Prob(x¯21 − x¯02 < λ | µ2 = µ0 + δ)× Prob(I3|N3) γ3
γ2 + γ3
The weighted average power when ”correct” enrollment decision is made, i.e., skip the
second stage enrollment at dose step 2 under LFC21 , or proceed to the second stage
enrollment under LFC22 , can be calculated as
G˜21 = Prob(I3|N3)
G˜22 = (γ2Prob(I2|N2) + γ3Prob(I3|N2))/(γ2 + γ3)
The optimal cut point at dose step 2 λ2 can be derived by minimize the maximum
opportunity loss as following:
L2(λ) =Max(G˜
2
1 − E(G21|λ), G˜22 − E(G22|λ))
2. At the lowest dose step (dose 1), observed drug effect after the first stage enrollment is
x¯11 − x¯01. Notice that the drug effect configuration for dose level 2 and 3 under least
favorable configuration LFC11 is the same as LFC
2
2 (µ2 = µ3 = µ0 + δ). Using the cut
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point λ at dose step 1, the expected weighted average power under LFC11 (µ1 = µ0 and
µ3 = µ2 = µ0 + δ) and LFC
1
2 (µ1 = µ2 = µ3 = µ0 + δ) can be calculated as
E(G11|λ, λ2) = Prob(x¯11 − x¯01 > λ|µ1 = µ0)× (γ2Prob(I2|N1) + γ3Prob(I3|N1))
/(γ2 + γ3) + Prob(x¯11 − x¯01 < λ|µ1 = µ0)× E(G22|λ2)
E(G12|λ, λ) = Prob(x¯11 − x¯01 > λ|µ1 = µ0 + δ)
×(γ1Prob(I1|N1) + γ2Prob(I2|N1) + γ3Prob(I3|N1))/(γ1 + γ2 + γ3)
+Prob(x¯11 − x¯01 < λ|µ1 = µ0 + δ)× E(G22|λ2)
γ2 + γ3
γ1 + γ2 + γ3
The weighted average power when ”correct” enrollment decision is made, i.e., skip the
second stage enrollment at dose step 1 under LFC11 , or proceed to the second stage
enrollment under LFC12 , can be calculated as
G˜11 = (γ2Prob(I2|N2) + γ3Prob(I3|N2))/(γ2 + γ3)
G˜12 = (γ1Prob(I1|N1) + γ2Prob(I2|N1) + γ3Prob(I3|N1))/(γ1 + γ2 + γ3)
The optimal cut point at dose step 1 λ1 can be derived by minimize the maximum
opportunity loss as following:
L1(λ) =Max(G˜
1
1 − E(G11|λ, λ2), G˜12 − E(G12|λ, λ2))
In general, in a k dose group dose escalation study, the cut point at dose level i can be
derived by minimizing the maximum opportunity loss:
Li(λ) =Max(G˜
i
1 − E(Gi1|λ, λi+1, λi+2, . . . , λk−1), G˜i2 − E(Gi2|λ, λi+1, λi+2, . . . , λk−1))
The search for optimal critical values can be done by using numerical methods since the
analytic methods are not available to solve the optimal cut point values. In most clinical
studies where the actual response is a dichotomous variable, and the values of the cut points
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are restricted to a set of limited number of integers. The numerical search of the critical
values can be performed by comparing the maximum opportunity loss among all possible
choices. When a continuous dose response is used, the maximum loss function about the cut
points is generally unimodal, which makes the efficient numerical search feasible. However,
computing algorithm to search for the continuous cut point is not pursued in this thesis.
4.3.3 Optimal Adaptive Design When Simultaneous Confidence Intervals are
Used to Analyze the Study Data
Similar conservative stage-wise optimization approach to derive the values of the cut points
for adaptive design is proposed when inference of simultaneous confidence intervals is used to
analyze the study data. The least favorable configurations LFCi1 and LFC
i
2 (i = 1, 2, . . . , k−
1) defined in Section 4.3.2 have the same implication: they are the configurations under
which that the probability of making the unfavorable decisions of enrollment after interim
look is the biggest, while the weighted average power to identify all effective dose levels is the
smallest. The proof of that the probability of making the unfavorable decisions of enrollment
after interim look is the biggest is the same as I did earlier in the chapter and will not be
repeated here.
Suppose after the adaptive study enrollment is finished, dose group k − h + 1, k − h +
2, . . . , k are fully enrolled and thus enter the final analysis, and the effective dose groups are
k− r+ 1, k− r+ 2, . . . , k. In other words, there are r dose groups that are effective relative
to the control group and h dose groups that enter the analysis. Let t be the maximum of
k − r + 1 and k − s + 1. Write the estimates of the drug response at the control group
and each dose group as x¯0, x¯t, . . . , x¯k. Considering the max-min procedure in deriving the
simultaneous confidence intervals, we have the expression of G as:
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G =
k∑
i=t
γiPr(Ii) /
k∑
i=t
γi
=
k∑
i=t
γiPr(Reject Hi0) /
k∑
i=t
γi
=
k∑
i=t
γiPr(max
l6i
{(x¯l − x¯0) /
√
σ2/ni + σ2/n0} > mαΣ,h) /
k∑
i=t
γi
(4.2)
where mαΣ,h is the critical value of simultaneous confidence intervals discussed in Chapter
2. The isotonic assumption of dose dose effect means and the use of max-min procedure to
derive the lower bounds of SCI ensures that that Pr(Ik) > Pr(Ik−1) > . . . > Pr(Ik−r+1),
which in turns indicates that the weighted average power to identify all effective dose levels is
the smallest under LFCi1 and LFC
i
2. Therefore the least favorable configurations LFC
i
1 and
LFCi2 have the same implications when the approach of simultaneous confidence intervals is
used.
In order to adjust for the adaptive procedure used in study subjects enrollment, I propose
to use the following approach to derived the critical value for simultaneous confidence inter-
vals. Suppose the common standard deviation of normally distributed drug effect variables is
σ. At dose level i (i 6 k−1), after the first stage enrollment x¯i1− x¯0i > λi is observed for the
first time, and thus dose i and all the higher dose groups are fully enrollment, with sample
size in each treatment group as n. The 1 − α one-sided simultaneous confidence intervals
for comparisons between each dose group and the control group (µj − µ0, i 6 j 6 k) can be
obtained by inverting the rejection region of the following simultaneous one-sided hypothesis
testing with type I error rate α:
H0 : There is at least one j, i 6 j 6 k, such that µj 6 µ0
H1 : µj > µ0 for all i 6 j 6 k
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The desired rejection region can be obtained by solving the critical value m in the following
equation:
Prob(
⋃
i6j6k
{x¯j − x¯0 > miσ 1√
2/n
| µj = µ0}) = α
Take into consideration the adaptive enrollment that we use, and the positive correlations
between the drug effect estimate of any dose group higher than dose i, x¯h− x¯0 (i 6 h 6 k),
and the first stage observed drug effect of any dose group lower tha dose i, x¯l1−x¯0 (1 6 l < i),
the following inequality can be used to find the critical values of the simultaneous confidence
intervals:
Prob(
⋃
i6j6k
{x¯j − x¯0 < miσ 1√
2/n
|µj = µ0}|x¯i1 − x¯0i > λi; x¯j1 − x¯0j 6 λj for 1 6 j < i)
6 Prob(
⋃
i6j6k
{x¯j − x¯0 > miσ 1√
2/n
} | µ1 = . . . = µj = µ0; x¯i1 − x¯0i > λi)
= α
The marginal multivariate distribution of observed relative drug effects x¯j − x¯0 (i 6 j 6 k)
can be obtained using the Monte Carlo Composition algorithm with rejective/acceptance
method. The computing algorithm introduced in chapter 2 then can be used to search for
the critical value m using the empirical estimates of the correlation matrix. The max-min
procedure then can be applied to obtain the simultaneous confidence intervals under order
restriction µi 6 µi+1 6 . . . µk:
µj − µ0 > max
l6j
{x¯l − x¯0 −miσ 1√
2/n
} for all i 6 j 6 k
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4.3.4 Case Study
In this section I will illustrate the above optimal adaptive dose study designs using an
example study. The example dose escalation study I am using has only three dose levels for
ease of presentation. However, the design approach, analysis approaches and programming
algoruthm can be readily extended to dose escalation studies with more than three dose
levels.
As in the previous chapters, the dose response is measured by a binary variable and we
use logarithm of the odds ratio between each dose group and the control group as the study
endpoint. The binary variable represents treatment success of the target disease in each
study group. Write the probability of observing the treatment success within the follow up
period of the study as p0 in the control group, and pi in dose group i, where i = 1, 2 or 3.
Suppose we know in advance that the expected success rate in the control group is 10%, and
we decide that for the experiment drug to be considered as effective, the success rate needs
to be increased to no less than 14%.
Write zi = log(
pi/(1−pi)
p0/(1−p0)), i = 1, 2, 3. Dose level i will be declared to be effective if
the null hypothesis Hi0 : zi 6 0 is rejected by one-sided test with alternative hypothesis
H1i : zi > 0, and type I error probability at 0.05. The analysis approach to be used to
conduct the test is the General Max-min Approach of Simultaneous Confidence Intervals we
proposed in Chapter 2, or the Modified Stepdown Testing Procedure in Adaptive Dose Study
with a Binary Endpoint we proposed in Chapter 3. Computer programming algorithms are
developed based on the backward induction approach introduced in this Chapter.
The number of subjects at the first stage of the adaptive design in a dose escalation study
is usually decided largely based on clinical considerations. Sufficient number of subjects need
to be studied for the mechanism of drug effect and safety concern before the study can be
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escalated to the next higher dose level. Simulation studies with different numbers of subjects
at the first stage are performed to explore the design efficiency variation when the number of
subjects enrolled at the first stage vary. Another parameter of such study that has multiple
treatment groups and a common control group is the ratio of sample sizes between the
common control and each treatment group. Williams [36] concluded that, to achieve the
highest power, the ratio should be equal to approximately the square root of the number of
treatment groups. However, in a phase II dose escalation study, clinicians usually prefer to
have more subjects in the treatment groups to evaluate various safety aspect of the drug.
Therefore, we use the same number of subjects in each dose group and the control group.
The total sample size for the three dose groups and the control group is 4000.
The cut points of adaptive design are listed in the following tables. These cut points are
decided in terms of the difference in numbers of treatment success between the control group
and each dose group. Some of the notations in the tables are described as following:
Weights: The weights of G based on the number of effective dose levels identified (1 dose:
2 doses: 3 dose)
Dose: The dose level at which the adaptive sampling performed.
M : The cut points defined in terms of the difference between the number of the observed
success in dose group i (mi1) and the number of treatment success in the control group
(m0i) after the first stage enrollment :mi1 −moi
p1: The probability that the dose group has second stage enrollment under LFC1
p2: The probability that the dose group has second stage enrollment under LFC2
G2: Weighted average power under LFC2 with adaptive design
G˜2: Weighted average power under LFC2 without adaptive design
G1: Weighted average power under LFC1 with adaptive design
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G˜1: Weighted average power under LFC1 without adaptive design
In each of the three tables, the benefit of using adaptive enrollment when compared to
the non-adaptive enrollment with equal sample size in each treatment group is clearly seen.
The weighted average power is substantially improved (G1 vs G˜1) when the current dose level
is not effective, while the decrease of weighted average power (G2 vs G˜2) is almost negligible
when the current dose level is actually effective. The flexibility of using appropriate weights
in the weighted average power based on clinical considerations, and the easy to perform
adaptive sampling rules make this design very attractive in practice.
It can also be noticed that the critical values for the adaptive design with stepdown
testing procedure are consistently larger than the critical values for the adaptive design
with simultaneous confidence intervals. This confirms our previous prediction that limiting
enrollment in ineffective dose groups has bigger impact when the study data are analyzed
using SCI, since it both increases sample sizes in effective dose groups and enables us to
focus on less dose levels. Also by comparing the weighted average power across three tables,
we can see that the variation of the weighted average power under both Least Favorable
Configurations remain fairly stable given the same weights.
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Table 11: Adaptive Dose Study Design: 200 Subjects Enrolled at the First Stage of Each
Dose Level
Analysis Approach: Stepdown Testing Procedure
Weights Dose M p1 p2 G2 G˜2 G1 G˜1
1:2:3 2 1 0.467 0.877 0.850 0.869 0.958 0.917
1:2:3 1 5 0.226 0.705 0.669 0.682 0.827 0.749
1:3:5 2 0 0.533 0.906 0.837 0.846 0.958 0.917
1:3:5 1 4 0.279 0.756 0.642 0.654 0.805 0.722
1:3:7 2 0 0.533 0.906 0.838 0.846 0.958 0.917
1:3:7 1 3 0.338 0.802 0.604 0.615 0.799 0.722
1:4:9 2 0 0.533 0.906 0.827 0.840 0.958 0.917
1:4:9 1 3 0.338 0.802 0.604 0.620 0.787 0.710
Analysis Approach: Simultaneous Confidence Intervals
Weights Dose M p1 p2 G2 G˜2 G1 G˜1
1:2:3 2 1 0.467 0.877 0.882 0.900 0.908 0.832
1:2:3 1 6 0.179 0.650 0.776 0.786 0.825 0.716
1:3:5 2 0 0.533 0.906 0.859 0.877 0.908 0.832
1:3:5 1 5 0.226 0.705 0.747 0.757 0.788 0.676
1:3:7 2 0 0.533 0.905 0.859 0.877 0.908 0.832
1:3:7 1 4 0.279 0.756 0.694 0.710 0.780 0.676
1:4:9 2 0 0.533 0.905 0.844 0.865 0.908 0.832
1:4:9 1 4 0.279 0.756 0.697 0.710 0.774 0.656
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Table 12: Adaptive Dose Study Design: 300 Subjects Enrolled at the First Stage of Each
Dose Level
Analysis Approach: Stepdown Testing Procedure
Weights Dose M p1 p2 G2 G˜2 G1 G˜1
1:2:3 2 3 0.367 0.884 0.845 0.867 0.960 0.909
1:2:3 1 6 0.227 0.794 0.679 0.682 0.817 0.747
1:3:5 2 2 0.419 0.907 0.831 0.853 0.956 0.909
1:3:5 1 6 0.227 0.794 0.647 0.654 0.799 0.722
1:3:7 2 2 0.419 0.907 0.831 0.853 0.956 0.909
1:3:7 1 5 0.270 0.828 0.613 0.625 0.795 0.722
1:4:9 2 1 0.473 0.927 0.829 0.846 0.951 0.909
1:4:9 1 5 0.270 0.828 0.612 0.622 0.791 0.710
Analysis Approach: Simultaneous Confidence Intervals
Weights Dose M p1 p2 G2 G˜2 G1 G˜1
1:2:3 2 3 0.367 0.884 0.882 0.890 0.927 0.818
1:2:3 1 8 0.153 0.714 0.795 0.786 0.840 0.715
1:3:5 2 2 0.419 0.907 0.856 0.865 0.918 0.818
1:3:5 1 8 0.153 0.714 0.762 0.756 0.809 0.675
1:3:7 2 2 0.419 0.907 0.856 0.865 0.918 0.818
1:3:7 1 7 0.188 0.756 0.709 0.709 0.804 0.675
1:4:9 2 2 0.419 0.907 0.841 0.852 0.918 0.818
1:4:9 1 7 0.188 0.756 0.710 0.710 0.784 0.655
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Table 13: Adaptive Dose Study Design: 400 Subjects Enrolled at the First Stage of Each
Dose Level
Analysis Approach: Stepdown Testing Procedure
Weights Dose M p1 p2 G2 G˜2 G1 G˜1
1:2:3 2 5 0.298 0.895 0.841 0.854 0.959 0.899
1:2:3 1 9 0.158 0.793 0.681 0.682 0.821 0.747
1:3:5 2 4 0.360 0.914 0.825 0.834 0.955 0.899
1:3:5 1 8 0.188 0.823 0.653 0.654 0.800 0.722
1:3:7 2 4 0.340 0.914 0.825 0.839 0.955 0.899
1:3:7 1 7 0.222 0.850 0.635 0.797 0.625 0.722
1:4:9 2 3 0.384 0.930 0.821 0.831 0.952 0.899
1:4:9 1 7 0.222 0.850 0.619 0.622 0.785 0.710
Analysis Approach: Simultaneous Confidence Intervals
Weights Dose M p1 p2 G2 G˜2 G1 G˜1
1:2:3 2 5 0.297 0.895 0.880 0.889 0.930 0.803
1:2:3 1 11 0.107 0.725 0.803 0.806 0.840 0.715
1:3:5 2 4 0.339 0.913 0.851 0.853 0.923 0.803
1:3:5 1 10 0.131 0.760 0.772 0.786 0.803 0.675
1:3:7 2 4 0.339 0.913 0.851 0.853 0.923 0.803
1:3:7 1 9 0.157 0.793 0.719 0.724 0.799 0.675
1:4:9 2 3 0.383 0.929 0.840 0.839 0.915 0.803
1:4:9 1 9 0.157 0.793 0.722 0.722 0.789 0.655
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5.0 FUTURE RESEARCH PLAN
Although the General Max-Min procedure for deriving the simultaneous confidence intervals
is developed under the assumption of multivariate normal distribution, it is certainly feasible
to extend the approach to other multivariate distribution. Specifically, in a clinical study
with adaptive enrollment design, the distribution of the study data is not normal even if the
original drug responses are normally distributed. I plan to extend the computing approach
based on Somerville’s algorithm to simulate the critical values of the simultaneous confidence
intervals with the biased sample from adaptive clinical study.
Schoenfeld [22] (1986) suggested that, under the assumption of isotonic dose response,
one can use the isotonic regression estimates and likelihood ratio test to derive the critical
point for one-sided test in dose study. The test can improve the efficiency over the usual
test performed individually at each dose level without considering the monotonicity of the
dose response means. When the dose response means at the tested dose levels are very close
to each other, which is usually the case in well-studied disease areas, Schoenfeld’s test is
especially powerful. Therefore, by adopting Schoenfeld’s test at each step of a stepdown
testing procedure, we can increase the power the testing procedure. However, Schoenfeld’s
approach is limited to the cases of independent dose responses. In fact, most of the isotonic
regression related research is limited to the independent cases. I plan to develop a testing
procedure similar to Schoenfeld’s for correlated dose response, which also utilizes the isotonic
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dose response assumption to improves the power of the test.
As we have illustrated in the previous chapter, the optimal parameters of the adaptive
design depend on the approach used to analyze the study data. Once we have improved
the analysis methods, the adaptive design parameters should be updated, too. Also I plan
to extend the design approach to the more general situations when the dose study can be
restricted by different clinical and logistic constraints. Also I plan to explore the adaptive
design of dose study when the study endpoint is an ordinal and/or Poisson random variable.
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APPENDIX A
SAS PROGRAMS USED TO DERIVE THE CRITICAL VALUES OF
MODIFIDED SIMULTANEOUS CONFIDENCE INTERVALS
/* Input parameter for Somerville Simulation Programs
SAS/IML program for calculating critical values of multiple
comparison procedures.
Input : (Required parameters)
swcov : Flag to include var-covar matrix (=0) or not (=1)
swtype : Type of multiple comparison procedure
conf : Confidence level
givense : User requested SE of estimates, if alternate
procedure is used
k : Number of treatment groups
seed : Seed for random number generator
ndenom : Degrees of freedom
mocar : Number of random directions
irep : Number of prliminary estimates (if negative,
alternate procedure is performed)
(Optional parameters)
mm : Number of contrasts (if swtype = 0)
vc : Var-covar matrix (if swcov = 0)
contr : Contrasts (if swtype = 0 or 20)
icontrol: Control group {if [(swtype=4 OR 5) AND (swcov=0)]
OR [(swtype=9)]}
iflo : Lower bound for peak (swtype = 10)
ighi : Higher bound for peak (swtype = 10)
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znn : Vector of sample sizes (swtype = 11-15)
Output :
*/
** Derive critical values when difference of probailitie is used **;
%macro rn(nn1=, nn2=, nn3=, nn4=, nn5=, nn6=, nn7=);
%do ii=1 %to 2;
%do iii=1 %to 7;
%let n&iii=%scan(&&nn&iii,&ii);
%end;
data _null_;
array varlist v1-v14;
do i=4 to 17;
varlist(i-3)=(i/100)*(1-i/100);
end;
call symput(’var4’, trim(left(put(v1, 8.6))));
call symput(’var5’, trim(left(put(v2, 8.6))));
call symput(’var6’, trim(left(put(v3, 8.6))));
call symput(’var7’, trim(left(put(v4, 8.6))));
call symput(’var8’, trim(left(put(v5, 8.6))));
call symput(’var9’, trim(left(put(v6, 8.6))));
call symput(’var10’, trim(left(put(v7, 8.6))));
call symput(’var11’, trim(left(put(v8, 8.6))));
call symput(’var12’, trim(left(put(v9, 8.6))));
call symput(’var13’, trim(left(put(v10, 8.6))));
call symput(’var14’, trim(left(put(v11, 8.6))));
call symput(’var15’, trim(left(put(v12, 8.6))));
call symput(’var16’, trim(left(put(v13, 8.6))));
call symput(’var17’, trim(left(put(v14, 8.6))));
run;
%let charc1=" &var10 &var10 &var10 &var10 &var10 &var10 &var10";
%let charc2=" &var10 &var12 &var12 &var12 &var12 &var12 &var12";
%let charc3=" &var10 &var8 &var8 &var8 &var8 &var8 &var8 ";
%let charc4=" &var10 &var12 &var11 &var10 &var9 &var8 &var7 ";
79
%let charc5=" &var10 &var12 &var12 &var10 &var10 &var8 &var8 ";
%let charc6=" &var10 &var12 &var12 &var12 &var8 &var8 &var8 ";
%let charc7=" &var10 &var9 &var8 &var7 &var6 &var6 &var4 ";
%let charc8=" &var10 &var17 &var16 &var15 &var14 &var13 &var12";
%let charc9=" &var10 &var12 &var8 &var8 &var8 &var8 &var8 ";
%let charc10="&var10 &var8 &var8 &var8 &var8 &var8 &var12";
%do j=1 %to 10;
data _null_;
array varlist v1-v7;
%do i=1 %to 7;
varlist(&i)=%scan(&&charc&j,&i," " )/&&n&i;
%end;
call symput(’va1’, trim(left(put(v1, 8.6))));
call symput(’va2’, trim(left(put(v2, 8.6))));
call symput(’va3’, trim(left(put(v3, 8.6))));
call symput(’va4’, trim(left(put(v4, 8.6))));
call symput(’va5’, trim(left(put(v5, 8.6))));
call symput(’va6’, trim(left(put(v6, 8.6))));
call symput(’va7’, trim(left(put(v7, 8.6))));
run;
options nosource;
proc iml;
/* INSERT SITUATION PARAMETERS HERE */
swcov = 0 ;
swtype = 0 ;
conf = .975 ;
givense= 999 ;
k = 7 ;
seed = 1893 ;
ndenom = -1 ;
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mocar = 5000 ;
irep = 10 ;
mm = 6 ;
vc={&va1 . . . . . . ,
0 &va2 . . . . . ,
0 0 &va3 . . . . ,
0 0 0 &va4 . . . ,
0 0 0 0 &va5 . . ,
0 0 0 0 0 &va6 . ,
0 0 0 0 0 0 &va7 } ;
contr={1 0 0 0 0 0 -1,
1 0 0 0 0 -1 0,
1 0 0 0 -1 0 0,
1 0 0 -1 0 0 0,
1 0 -1 0 0 0 0,
1 -1 0 0 0 0 0};
/* END SITUATION PARAMETERS */
............................................................
(simulation programs by Somerville)
%end;
%end;
*quit;
%mend;
%rn(nn1=1500 1500, nn2=500 500, nn3=500 500, nn4=1000 500, nn5=1000 500,
nn6=1000 1000, nn7=1000 1000)
** Derive critical values when relative risk is used **;
%macro rn(nn1=, nn2=, nn3=, nn4=, nn5=, nn6=, nn7=);
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%do ii=1 %to 2;
%do iii=1 %to 7;
%let n&iii=%scan(&&nn&iii,&ii);
%end;
data _null_;
array varlist v1-v17;
do i=4 to 17;
varlist(i-3)=(1-i/100);
end;
call symput(’var4’, trim(left(put(v1, 8.6))));
call symput(’var5’, trim(left(put(v2, 8.6))));
call symput(’var6’, trim(left(put(v3, 8.6))));
call symput(’var7’, trim(left(put(v4, 8.6))));
call symput(’var8’, trim(left(put(v5, 8.6))));
call symput(’var9’, trim(left(put(v6, 8.6))));
call symput(’var10’, trim(left(put(v7, 8.6))));
call symput(’var11’, trim(left(put(v8, 8.6))));
call symput(’var12’, trim(left(put(v9, 8.6))));
call symput(’var13’, trim(left(put(v10, 8.6))));
call symput(’var14’, trim(left(put(v11, 8.6))));
call symput(’var15’, trim(left(put(v12, 8.6))));
call symput(’var16’, trim(left(put(v13, 8.6))));
call symput(’var17’, trim(left(put(v14, 8.6))));
run;
%let charc1="&var10 &var10 &var10 &var10 &var10 &var10 &var10";
%let charc2="&var10 &var12 &var12 &var12 &var12 &var12 &var12";
%let charc3="&var10 &var8 &var8 &var8 &var8 &var8 &var8";
%let charc4="&var10 &var12 &var11 &var10 &var9 &var8 &var7";
%let charc5="&var10 &var12 &var12 &var10 &var10 &var8 &var8";
%let charc6="&var10 &var12 &var12 &var12 &var8 &var8 &var8";
%let charc7="&var10 &var9 &var8 &var7 &var6 &var6 &var4";
%let charc8="&var10 &var17 &var16 &var15 &var14 &var13 &var12";
%let charc9="&var10 &var12 &var8 &var8 &var8 &var8 &var8";
%let charc10="&var10 &var8 &var8 &var8 &var8 &var8 &var12";
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%do j=1 %to 10;
options nosource;
data _null_;
array varlist v1-v7;
%do i=1 %to 7;
p_1=%scan(&&charc&j, &i, " ");
varlist(&i)=p_1/(&&n&i*(1-p_1));
%end;
call symput(’va1’, trim(left(put(v1, 8.6))));
call symput(’va2’, trim(left(put(v2, 8.6))));
call symput(’va3’, trim(left(put(v3, 8.6))));
call symput(’va4’, trim(left(put(v4, 8.6))));
call symput(’va5’, trim(left(put(v5, 8.6))));
call symput(’va6’, trim(left(put(v6, 8.6))));
call symput(’va7’, trim(left(put(v7, 8.6))));
run;
proc iml;
/* INSERT SITUATION PARAMETERS HERE */
swcov = 0 ;
swtype = 0 ;
conf = .975 ;
givense= 999 ;
k = 7 ;
seed = 1893 ;
ndenom = -1 ;
mocar = 5000 ;
irep = 10 ;
mm = 6 ;
vc={&va1 . . . . . . ,
0 &va2 . . . . . ,
0 0 &va3 . . . . ,
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0 0 0 &va4 . . . ,
0 0 0 0 &va5 . . ,
0 0 0 0 0 &va6 . ,
0 0 0 0 0 0 &va7 } ;
contr={1 0 0 0 0 0 -1,
1 0 0 0 0 -1 0,
1 0 0 0 -1 0 0,
1 0 0 -1 0 0 0,
1 0 -1 0 0 0 0,
1 -1 0 0 0 0 0};
/* END SITUATION PARAMETERS */
............................................................
(simulation programs by Somerville)
%end;
%end;
*quit;
%mend;
%rn(nn1=1500 1500, nn2=500 500, nn3=500 500, nn4=1000 500, nn5=1000 500,
nn6=1000 1000, nn7=1000 1000)
** Derive critical values when log odds ratio is used **;
%macro rn(nn1=, nn2=, nn3=, nn4=, nn5=, nn6=, nn7=);
%do ii=1 %to 2;
%do iii=1 %to 7;
%let n&iii=%scan(&&nn&iii,&ii);
%end;
data _null_;
array varlist v1-v17;
do i=4 to 17;
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varlist(i-3)=1/(i/100)+1/(1-i/100);
end;
call symput(’var4’, trim(left(put(v1, 8.6))));
call symput(’var5’, trim(left(put(v2, 8.6))));
call symput(’var6’, trim(left(put(v3, 8.6))));
call symput(’var7’, trim(left(put(v4, 8.6))));
call symput(’var8’, trim(left(put(v5, 8.6))));
call symput(’var9’, trim(left(put(v6, 8.6))));
call symput(’var10’, trim(left(put(v7, 8.6))));
call symput(’var11’, trim(left(put(v8, 8.6))));
call symput(’var12’, trim(left(put(v9, 8.6))));
call symput(’var13’, trim(left(put(v10, 8.6))));
call symput(’var14’, trim(left(put(v11, 8.6))));
call symput(’var15’, trim(left(put(v12, 8.6))));
call symput(’var16’, trim(left(put(v13, 8.6))));
call symput(’var17’, trim(left(put(v14, 8.6))));
run;
%let charc1="&var10 &var10 &var10 &var10 &var10 &var10 &var10";
%let charc2="&var10 &var12 &var12 &var12 &var12 &var12 &var12";
%let charc3="&var10 &var8 &var8 &var8 &var8 &var8 &var8";
%let charc4="&var10 &var12 &var11 &var10 &var9 &var8 &var7";
%let charc5="&var10 &var12 &var12 &var10 &var10 &var8 &var8";
%let charc6="&var10 &var12 &var12 &var12 &var8 &var8 &var8";
%let charc7="&var10 &var9 &var8 &var7 &var6 &var6 &var4";
%let charc8="&var10 &var17 &var16 &var15 &var14 &var13 &var12";
%let charc9="&var10 &var12 &var8 &var8 &var8 &var8 &var8";
%let charc10="&var10 &var8 &var8 &var8 &var8 &var8 &var12";
%do j=1 %to 10;
options nosource;
data _null_;
array varlist v1-v7;
%do i=1 %to 7;
varlist(&i)=%scan(&&charc&j, &i, " ")/&&n&i;
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%end;
call symput(’va1’, trim(left(put(v1, 8.6))));
call symput(’va2’, trim(left(put(v2, 8.6))));
call symput(’va3’, trim(left(put(v3, 8.6))));
call symput(’va4’, trim(left(put(v4, 8.6))));
call symput(’va5’, trim(left(put(v5, 8.6))));
call symput(’va6’, trim(left(put(v6, 8.6))));
call symput(’va7’, trim(left(put(v7, 8.6))));
run;
proc iml;
/* INSERT SITUATION PARAMETERS HERE */
swcov = 0 ;
swtype = 0 ;
conf = .975 ;
givense= 999 ;
k = 7 ;
seed = 1893 ;
ndenom = -1 ;
mocar = 5000 ;
irep = 10 ;
mm = 6 ;
vc={&va1 . . . . . . ,
0 &va2 . . . . . ,
0 0 &va3 . . . . ,
0 0 0 &va4 . . . ,
0 0 0 0 &va5 . . ,
0 0 0 0 0 &va6 . ,
0 0 0 0 0 0 &va7 } ;
contr={1 0 0 0 0 0 -1,
1 0 0 0 0 -1 0,
1 0 0 0 -1 0 0,
1 0 0 -1 0 0 0,
1 0 -1 0 0 0 0,
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1 -1 0 0 0 0 0};
/* END SITUATION PARAMETERS */
%end;
%end;
*quit;
%mend;
%rn(nn1=1500 1500, nn2=500 500, nn3=500 500, nn4=1000 500, nn5=1000 500,
nn6=1000 1000, nn7=1000 1000)
** Derive critical values when difference of arcsinc of square root of
probailitie is used **;
%macro rn(nn1=, nn2=, nn3=, nn4=, nn5=, nn6=, nn7=);
%do ii=1 %to 2;
%do iii=1 %to 7;
%let n&iii=%scan(&&nn&iii,&ii);
%end;
data _null_;
array varlist v1-v14;
do i=4 to 17;
varlist(i-3)=0.25;
end;
call symput(’var4’, trim(left(put(v1, 8.6))));
call symput(’var5’, trim(left(put(v2, 8.6))));
call symput(’var6’, trim(left(put(v3, 8.6))));
call symput(’var7’, trim(left(put(v4, 8.6))));
call symput(’var8’, trim(left(put(v5, 8.6))));
call symput(’var9’, trim(left(put(v6, 8.6))));
call symput(’var10’, trim(left(put(v7, 8.6))));
call symput(’var11’, trim(left(put(v8, 8.6))));
call symput(’var12’, trim(left(put(v9, 8.6))));
call symput(’var13’, trim(left(put(v10, 8.6))));
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call symput(’var14’, trim(left(put(v11, 8.6))));
call symput(’var15’, trim(left(put(v12, 8.6))));
call symput(’var16’, trim(left(put(v13, 8.6))));
call symput(’var17’, trim(left(put(v14, 8.6))));
run;
%let charc1="&var10 &var10 &var10 &var10 &var10 &var10 &var10";
%let charc2="&var10 &var12 &var12 &var12 &var12 &var12 &var12";
%let charc3="&var10 &var8 &var8 &var8 &var8 &var8 &var8";
%let charc4="&var10 &var12 &var11 &var10 &var9 &var8 &var7";
%let charc5="&var10 &var12 &var12 &var10 &var10 &var8 &var8";
%let charc6="&var10 &var12 &var12 &var12 &var8 &var8 &var8";
%let charc7="&var10 &var9 &var8 &var7 &var6 &var6 &var4";
%let charc8="&var10 &var17 &var16 &var15 &var14 &var13 &var12";
%let charc9="&var10 &var12 &var8 &var8 &var8 &var8 &var8";
%let charc10="&var10 &var8 &var8 &var8 &var8 &var8 &var12";
%do j=1 %to 10;
options nosource;
data _null_;
array varlist v1-v7;
%do i=1 %to 7;
varlist(&i)=%scan(&&charc&j,&i," " )/&&n&i;
%end;
call symput(’va1’, trim(left(put(v1, 8.6))));
call symput(’va2’, trim(left(put(v2, 8.6))));
call symput(’va3’, trim(left(put(v3, 8.6))));
call symput(’va4’, trim(left(put(v4, 8.6))));
call symput(’va5’, trim(left(put(v5, 8.6))));
call symput(’va6’, trim(left(put(v6, 8.6))));
call symput(’va7’, trim(left(put(v7, 8.6))));
run;
proc iml;
88
/* INSERT SITUATION PARAMETERS HERE */
swcov = 0 ;
swtype = 0 ;
conf = .975 ;
givense= 999 ;
k = 7 ;
seed = 1893 ;
ndenom = -1 ;
mocar = 5000 ;
irep = 10 ;
mm = 6 ;
vc={&va1 . . . . . . ,
0 &va2 . . . . . ,
0 0 &va3 . . . . ,
0 0 0 &va4 . . . ,
0 0 0 0 &va5 . . ,
0 0 0 0 0 &va6 . ,
0 0 0 0 0 0 &va7 } ;
contr={1 0 0 0 0 0 -1,
1 0 0 0 0 -1 0,
1 0 0 0 -1 0 0,
1 0 0 -1 0 0 0,
1 0 -1 0 0 0 0,
1 -1 0 0 0 0 0};
/* END SITUATION PARAMETERS */
%end;
%end;
*quit;
%mend;
%rn(nn1=1500 1500, nn2=500 500, nn3=500 500, nn4=1000 500, nn5=1000 500,
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nn6=1000 1000, nn7=1000 1000)
** Programs to obtain max-min Simultaneous Confidence Intervals for
simulated data **;
libname save ’/proj/c5/combo/gurm/wbc_10107/analysis’;
libname dat ’/proj/c5/combo/gurm/wbc_10107/analysis/ana/proposal/programs’;
%macro simu(dat=,l=);
proc sort data=&dat out=simu; by situ;
run;
data ana6;
merge simu
dat.crit_multinorm;
by situ;
array crt{4} crit_p crit_ars crit_lod crit_lrr;
array low{4,6} low_p1-low_p6 low_ars1-low_ars6 low_lod1-low_lod6
low_lrr1-low_lrr6;
array up{4,6} up_p1-up_p6 up_ars1-up_ars6 up_lod1-up_lod6
up_lrr1-up_lrr6;
array wid{4,6} widp1-widp6 widars1-widars6 widlod1-widlod6
widlrr1-widlrr6;
array wid1{4,6} wid1p1-wid1p6 wid1ars1-wid1ars6 wid1lod1-wid1lod6
wid1lrr1-wid1lrr6;
array ral{4,6} dp_r1-dp_r6 dap_r1-dap_r6 lods_r1-lods_r6 lrr_r1-lrr_r6;
array indc{4} dp_i dap_i lods_i lrr_i;
array m{4,6} dp1-dp6 dap1-dap6 lods1-lods6 lrr1-lrr6;
array q{4,6} dpq1-dpq6 dapq1-dapq6 lodsq1-lodsq6 lrrq1-lrrq6;
do j=1 to 4;
indc(j)=1;
do h=1 to 6;
low(j,h)=ral(j,h)-q(j,h)*crt(j);
up(j,h)=ral(j,h)+q(j,h)*crt(j);
wid1(j,h)=up(j,h)-low(j,h);
do ii=1 to h;
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up(j,h)=min(ral(j,ii)+q(j,ii)*crt(j),up(j,h));
end;
do iii=h to 6;
low(j,h)=max(ral(j,iii)-q(j,iii)*crt(j),low(j,h));
end;
if m(j,h)>ral(j,h)+q(j,h)*crt(j) or m(j,h)<ral(j,h)
-q(j,h)*crt(j) then indc(j)=0;
wid(j,h)=up(j,h)-low(j,h);
end;
end;
widavp=mean(widp1, widp2, widp3, widp4, widp5, widp6);
widavars=mean(widars1, widars2, widars3, widars4, widars5, widars6);
widavlod=mean(widlod1, widlod2, widlod3, widlod4, widlod5, widlod6);
widavlrr=mean(widlrr1, widlrr2, widlrr3, widlrr4, widlrr5, widlrr6);
widav1p=mean(wid1p1, wid1p2, wid1p3, wid1p4, wid1p5, wid1p6);
widav1ars=mean(wid1ars1,wid1ars2,wid1ars3,wid1ars4,wid1ars5,wid1ars6);
widav1lod=mean(wid1lod1,wid1lod2,wid1lod3,wid1lod4,wid1lod5,wid1lod6);
widav1lrr=mean(wid1lrr1,wid1lrr2,wid1lrr3,wid1lrr4,wid1lrr5,wid1lrr6);
ratio_p=mean(widp1/wid1p1,widp2/wid1p2,widp3/wid1p3,widp4/wid1p4,
widp5/wid1p5,widp6/wid1p6);
ratio_ars=mean(widars1/wid1ars1,widars2/wid1ars2,widars3/wid1ars3,
widars4/wid1ars4,widars5/wid1ars5,widars6/wid1ars6);
ratio_lod=mean(widlod1/wid1lod1,widlod2/wid1lod2,widlod3/wid1lod3,
widlod4/wid1lod4,widlod5/wid1lod5,widlod6/wid1lod6);
ratio_lrr=mean(widlrr1/wid1lrr1,widlrr2/wid1lrr2,widlrr3/wid1lrr3,
widlrr4/wid1lrr4,widlrr5/wid1lrr5,widlrr6/wid1lrr6);
run;
title "&l";
proc means data=ana6 noprint;
var dp_i dap_i lods_i lrr_i;
class situ;
output out=out;
run;
data out1;
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set out;
where _stat_="MEAN";
keep situ dp_i dap_i lods_i lrr_i;
run;
proc print; run;
/*
proc means data=ana6 noprint;
var widavp widav1p ratio_p widavars widav1ars ratio_ars widavlod
widav1lod ratio_lod widavlrr widav1lrr ratio_lrr;
class situ;
output out=out;
run;
data out1;
set out;
where _stat_="MEAN";
keep situ widavp widav1p ratio_p widavars widav1ars ratio_ars
widavlod widav1lod ratio_lod widavlrr widav1lrr ratio_lrr;
run;
proc print; run;
*/
%mend;
%simu(dat=save.simu10000_uq, l=’control-30000 (123)-10000 (456)-20000’);
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APPENDIX B
SAS PROGRAMS USED TO DERIVED THE CRITICAL VALUES FOR
MIXTURE NORMAL APPROXIMATION APPROACH
options symbolgen mprint mlogic;
%macro monte(p=,pa=,ni1=,n01=,n0=,ni=,d=, msz=);
title "P=&p Pa=&pa Sample Size(TRT:Control): N1=&ni1:&n01 N=&ni:&n0";
data report;
dm=.; pct_low=.; err90=.; power90=.; pct_med=.; err95=.;
power95=.; pct_high=.; err975=.; power975=.; errr90=.; powerr90=.;
errr95=.; powerr95=.; errr975=.; powerr975=.;
run;
%let i=1;
%do %until(%scan(&d, &i, " ")=);
%let di=%scan(&d, &i);
%if %substr(&di,1,1)=n %then %do;
%let di=(-%substr(&di,2));
%end;
data tmp1;
d=&di;
p1=0;
** probability of crossing cut point after first stage under
null hypothesis **;
93
do m=0 to &n01;
do n=0 to &ni1;
if n-m>=&di then do;
if m>0 and n>0 then tmp=(probbnml(&p,&n01,m)-probbnml(&p,&n01,m-1))
*(probbnml(&p,&ni1,n)-probbnml(&p,&ni1,n-1));
if m=0 and n>0 then tmp=probbnml(&p,&n01,m)
*(probbnml(&p,&ni1,n)-probbnml(&p,&ni1,n-1));
if m>0 and n=0 then tmp=(probbnml(&p,&n01,m)-probbnml(&p,&n01,m-1))
*probbnml(&p,&ni1,n);
if m=0 and n=0 then tmp=probbnml(&p,&n01,m)*probbnml(&p,&ni1,n);
end;
else tmp=0;
p1=p1+tmp;
end;
end;
p90=trim(left(put((1-0.1/p1)*100,8.7)));
p95=trim(left(put((1-0.05/p1)*100,8.7)));
p975=trim(left(put((1-0.025/p1)*100,8.7)));
call symput("p90",p90);
call symput("p95",p95);
call symput("p975",p975);
p2=0;
** probability of crossing cut point after first stage under alternative
hypothesis **;
do m=0 to &n01;
do n=0 to &ni1;
if n-m>=&di then do;
if m>0 and n>0 then tmp=(probbnml(&p,&n01,m)-probbnml(&p,&n01,m-1))
*(probbnml(&pa,&ni1,n)-probbnml(&pa,&ni1,n-1));
if m=0 and n>0 then tmp=probbnml(&p,&n01,m)
*(probbnml(&pa,&ni1,n)-probbnml(&pa,&ni1,n-1));
if m>0 and n=0 then tmp=(probbnml(&p,&n01,m)-probbnml(&p,&n01,m-1))
*probbnml(&pa,&ni1,n);
if m=0 and n=0 then tmp=probbnml(&p,&n01,m)*probbnml(&pa,&ni1,n);
end;
else tmp=0;
p2=p2+tmp;
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end;
end;
p_1=trim(left(put(p1,8.7)));
p_2=trim(left(put(p2,8.7)));
call symput("p1",p_1);
call symput("p2",p_2);
run;
/*
proc print; var d p1 p2 p90 p95 p975; run;
*/
data tmp2;
s1=sqrt(1/(&p*&n01)+1/(&n01-&p*&n01)+1/(&p*&ni1)+1/(&ni1-&p*&ni1));
s2=sqrt(1/(&p*&n0)+1/(&n0-&p*&n0)+1/(&p*&ni)+1/(&ni-&p*&ni));
rho=(s2*s2)/(s1*s2);
pp95=trim(left(put(s2*probit(0.95),8.7)));
pp90=trim(left(put(s2*probit(0.9),8.7)));
pp975=trim(left(put(s2*probit(0.975),8.7)));
call symput("pp90",pp90);
call symput("pp95",pp95);
call symput("pp975",pp975);
** mixture normal distribution simulation **;
do i=1 to &msz;
m=ranbin(1009, &n01, &p);
if m+&di>0 then do;
n=m+&di-.5;
lambda=((n+0.5)/(&ni1-n+0.5)) / ((m+.5)/(&n01-m+.5));
end;
else if m+&di<=0 then lambda=0.00000001;
k=0;
do until(k>10000);
z1=rannor(k);
zi1=z1*s1;
if zi1>=log(lambda) then k=10001;
end;
z2=rannor(i);
zi=rho*s2*z1+sqrt(1-rho*rho)*s2*z2;
output;
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end;
** exact distribution simulation **;
n02=&n0-&n01;
ni2=&ni-&ni1;
i=0;
do until(i>=&msz);
m01=ranbin(1009,&n01,&p);
mi1=ranbin(1009,&ni1,&p);
if mi1-m01>=&di then do;
m02=ranbin(1009,n02,&p);
mi2=ranbin(1009,ni2,&p);
m0=m01+m02;
mi=mi1+mi2;
odds=((mi+0.5)/(&ni-mi+0.5))/((m0+0.5)/(&n0-m0+0.5));
zi=log(odds);
output;
i=i+1;
end;
end;*/
run;
** percentiles of the marginal distribution of testing statistics **;
proc univariate data=tmp2 noprint;
var zi;
output out=out mean=mean std=std pctlpts=&p90 &p95 &p975 pctlpre=pct_
pctlname=low med high ;
run;
/*
proc print data=out; run;
*/
data validate dat;
set out;
n02=&n0-&n01;
ni2=&ni-&ni1;
** error rates when adjusted critical values used **;
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err90=0;
err95=0;
err975=0;
** error rates when unadjusted critical values used **;
errr90=0;
errr95=0;
errr975=0;
** simulate the error rate **;
do i=1 to &msz;
m01=ranbin(1009,&n01,&p);
mi1=ranbin(1009,&ni1,&p);
if mi1-m01>=&di then do;
m02=ranbin(1009,n02,&p);
mi2=ranbin(1009,ni2,&p);
m0=m01+m02;
mi=mi1+mi2;
odds=((mi+0.5)/(&ni-mi+0.5))/((m0+0.5)/(&n0-m0+0.5));
z=log(odds);
output dat;
if z>pct_low then err90=err90+1;
if z>pct_med then err95=err95+1;
if z>pct_high then err975=err975+1;
if z>&pp90 then errr90=errr90+1;
if z>&pp95 then errr95=errr95+1;
if z>&pp975 then errr975=errr975+1;
end;
end;
err90=err90/&msz;
err95=err95/&msz;
err975=err975/&msz;
errr90=errr90/&msz;
errr95=errr95/&msz;
errr975=errr975/&msz;
** testing power when adjusted critical values used **;
power90=0;
power95=0;
power975=0;
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** testing power when unadjusted critical values used **;
powerr90=0;
powerr95=0;
powerr975=0;
do j=1 to &msz;
m01=ranbin(1009,&n01,&p) ;
mi1=ranbin(1009,&ni1,&pa);
if mi1-m01>=&di then do;
m02=ranbin(1009,&n0.-&n01,&p);
mi2=ranbin(1009,&ni.-&ni1,&pa);
m0=m01+m02;
mi=mi1+mi2;
odds=((mi+0.5)/(&ni-mi+0.5))/((m0+0.5)/(&n0-m0+0.5));
z=log(odds);
if z>pct_low then power90=power90+1;
if z>pct_med then power95=power95+1;
if z>pct_high then power975=power975+1;
if z>&pp90 then powerr90=powerr90+1;
if z>&pp95 then powerr95=powerr95+1;
if z>&pp975 then powerr975=powerr975+1;
end;
end;
power90=power90/&msz;
power95=power95/&msz;
power975=power975/&msz;
powerr90=powerr90/&msz;
powerr95=powerr95/&msz;
powerr975=powerr975/&msz;
dm=&di+0;
p1=&p1+0;
p2=&p2+0;
output validate;
keep z dm pct_low err90 power90 pct_med err95 power95 pct_high err975
power975 errr90 powerr90 errr95 powerr95 errr975 powerr975 p1 p2;
run;
/*
proc univariate data=dat;
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var z;
run;
*/
data report;
set report validate;
run;
%let i=%eval(&i+1); %end;
data report;
set report;
if _n_=1 then delete;
run;
proc print noobs;
var dm p1 pct_low err90 power90 errr90 powerr90;
run;
proc print noobs;
var dm p1 pct_med err95 power95 errr95 powerr95;
run;
proc print noobs;
var dm p1 pct_high err975 power975 errr975 powerr975;
run;
%mend;
%monte(p=0.1, pa=0.15, ni1=150, n01=150, n0=500, ni=500,
msz=200000, d=n8 n7 n6 n5 n4 n3 n2 n1 0 1 2 3 4 5);
%monte(p=0.1, pa=0.13, ni1=300, n01=300, n0=1000, ni=1000, msz=200000,
d=n15 n14 n13 n12 n11 n10 n9 n8 n7 n6 n5 n4 n3 n2 n1 0 1 2 3 4 5 6 7 8 9);
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APPENDIX C
SAS PROGRAMS USED TO OBTAIN THE OPTIMAL CUT POINTS
WHEN SCI APPROACHED IS USED
options symbolgen mprint mlogic;
%macro dsn(p=, pa=, ni1=, n01=, nni=, nn0=, msz=, r3=, r2=, r1=, seed=1009);
%let cr3=1.645;
%let cr2=2.080;
%let cr1=2.329;
data design;
dose=.; di=.; p1=.; p2=.; pct_pt2=.; pct_pt3=.; err2=.; err3=.; power2=.;
power3=.; g11=.; g01=.; g03=.; l1=.; g01=.; g02=.; l0=.; l_max=.; g_min=.;
run;
%do i=1 %to 2;
data report;
dose=.; di=.; p1=.; p2=.; pct_pt2=.; pct_pt3=.; err2=.; err3=.; power2=.;
power3=.; g11=.; g01=.; g03=.; l1=.; g01=.; g02=.; l0=.; l_max=.; g_min=.;
run;
%let dose=%eval(3-&i);
%let pdose=%eval(3-&i+1);
** sample sizes at dose step 1 and first stage of dose step 2 **;
%let ni=%sysevalf((&nni-&ni1)*(&dose-1)/(3-&dose+1)+&nni);
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%let n0=%sysevalf((&nn0-&n01)*(&dose-1)/(3-&dose+1)+&nn0);
%let ni2=%sysevalf((&nni-&ni1)*(&dose)/(3-&dose)+&nni);
%let n02=%sysevalf((&nn0-&n01)*(&dose)/(3-&dose)+&nn0);
data _null_;
** standard error of log odds ratio at dose level 1 & 2 **;
mu=log(&pa/(1-&pa)/(&p/(1-&p)));
s1=sqrt(1/(&p*&n01)+1/(&n01-&p*&n01)+1/(&p*&ni1)+1/(&ni1-&p*&ni1));
s2=sqrt(1/(&p*&n0)+1/(&n0-&p*&n0)+1/(&p*&ni)+1/(&ni-&p*&ni));
s3=sqrt(1/(&p*&n02)+1/(&n02-&p*&n02)+1/(&p*&ni2)+1/(&ni2-&p*&ni2));
rho=(s2*s2)/(s1*s2);
call symput("s1", trim(left(put(s1,10.6))));
call symput("s2", trim(left(put(s2,10.6))));
call symput("s3", trim(left(put(s3,10.6))));
call symput("rho", trim(left(put(rho,10.6))));
call symput("mu", trim(left(put(mu,10.6))));
run;
data rn1 rn2 rn3;
** simulated sample to be used in the program **;
do i=1 to &msz;
m=ranbin(&seed,&n01,&p);
z1=rannor(&seed);
z2=rannor(&seed);
output rn1;
end;
do i=1 to &msz;
m02=ranbin(&seed,&n0.-&n01,&p);
mi2=ranbin(&seed,&ni.-&ni1,&p);
m01=ranbin(&seed,&n01,&p) ;
mi1=ranbin(&seed,&ni1,&p);
output rn2;
end;
do i=1 to &msz;
m01=ranbin(&seed,&n01,&p);
mi1=ranbin(&seed,&ni1,&pa);
m02=ranbin(&seed,&n0.-&n01,&p);
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mi2=ranbin(&seed,&ni.-&ni1,&pa);
output rn3;
end;
run;
%do di=-50 %to 50;
%let va=0;
data _null_;
p1=0;
p2=0;
** calculated probabilites of second stage enrollment **;
min=max(0, &di);
max=min(&ni1, &n01+&di);
if max<&ni1 then do;
p1=p1+(1-probbnml(&p, &ni1,max));
p2=p2+(1-probbnml(&pa,&ni1,max));
end;
do n=min to max;
if n>0 then do;
p1=p1+(probbnml(&p,&ni1,n)-probbnml(&p,&ni1,n-1))
*probbnml(&p,&n01,n-&di);
p2=p2+(probbnml(&pa,&ni1,n)-probbnml(&pa,&ni1,n-1))
*probbnml(&p,&n01,n-&di);
end;
else if n=0 then do;
p1=p1+probbnml(&p,&ni1,n)*probbnml(&p,&n01,n-&di);
p2=p2+probbnml(&pa,&ni1,n)*probbnml(&p,&n01,n-&di);
end;
end;
call symput("p1",trim(left(put(p1,8.7))));
call symput("p2",trim(left(put(p2,8.7))));
err2=1-probnorm(&&cr&dose);
err3=1-probnorm(&&cr&pdose);
p95_2=(1-err2/p1)*100;
p95_3=(1-err3/p1)*100;
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call symput("p1", trim(left(put(p1,8.7))));
call symput("p2", trim(left(put(p2,8.7))));
call symput("p95_2",trim(left(put(p95_2,8.7))));
call symput("p95_3",trim(left(put(p95_3,8.7))));
if p1>err2 and p1>err3 and p1<0.99 then call symput("va","1");
run;
%if %substr(&va,1,1)=1 %then %do;
** derive simulated sample of testing statistics **;
data tmp2;
set rn1;
if m+&di>0 then do;
n=m+&di-.5;
lambda=((n+0.5)/(&ni1-n+0.5)) / ((m+.5)/(&n01-m+.5));
end;
else if m+&di<=0 then lambda=0.00000001;
zi1=z1*&s1;
if zi1>=log(lambda) then do;
zi=&rho*&s2*z1+sqrt(1-&rho*&rho)*&s2*z2;
output;
end;
run;
proc univariate data=tmp2 noprint;
var zi;
output out=out pctlpts=&p95_2 &p95_3 pctlpre=pct_ pctlname=pt2 pt3;
run;
data _null_;
set out;
call symput("pct_pt2", trim(left(put(pct_pt2,10.6))));
call symput("pct_pt3", trim(left(put(pct_pt3,10.6))));
run;
data _null_;
set rn2 end=last;
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retain err2 err3;
if _n_=1 then do;
err2=0;
err3=0;
end;
if mi1-m01>=&di then do;
m0=m01+m02;
mi=mi1+mi2;
odds=((mi+0.5)/(&ni-mi+0.5))/((m0+0.5)/(&n0-m0+0.5));
z=log(odds);
if z>&pct_pt2 then err2=err2+1;
if z>&pct_pt3 then err3=err3+1;
end;
if last then do;
call symput("err2", trim(left(put(err2/&msz,10.6))));
call symput("err3", trim(left(put(err3/&msz,10.6))));
end;
run;
data _null_;
** calculate power of the dose level with adaptive sampling **;
set rn3 end=last;
retain power2 power3;
if _n_=1 then do;
power2=0;
power3=0;
end;
if mi1-m01>=&di then do;
m0=m01+m02;
mi=mi1+mi2;
odds=((mi+0.5)/(&ni-mi+0.5))/((m0+0.5)/(&n0-m0+0.5));
z=log(odds);
if z>&pct_pt2 then power2=power2+1;
if z>&pct_pt3 then power3=power3+1;
end;
if last then do;
call symput("power2", trim(left(put(power2/&msz,10.6))));
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call symput("power3", trim(left(put(power3/&msz,10.6))));
end;
run;
/***********************************************************************
g01: gain when current dose not effective and use adaptive
g02: gain when current dose not effective and only enroll first stage
g03: gain when current dose not effective and enroll all subjects
g11: gain when current dose effective and use adaptive
g12: gain when current dose effective and enroll all subjects
************************************************************************/
data tmp2;
** calculate maximum opportunity losses **;
dose=&dose;
p1=&p1;
p2=&p2;
di=&di;
err2=&err2;
err3=&err3;
power2=&power2;
power3=&power3;
pct_pt2=&pct_pt2;
pct_pt3=&pct_pt3;
pow2=probnorm((&mu-&&cr&dose*&s2)/&s2);
pow3=probnorm((&mu-&&cr&pdose*&s3)/&s3);
err=probnorm(-&&cr&dose);
%if &dose=2 %then %do;
g01=err*p1+(1-err)*pow2*p1+pow3*(1-p1);
g11=(power2*&r2+p2*(1-power2/p2)*pow2*&r3+(1-&p2)*pow3*&r3)/&r2;
g02=pow3;
g12=(pow2*&r2+pow2*(1-pow2)*&r3)/&r2;
g03=err+(1-err)*pow2;
l0=g02-g01;
l1=g12-g11;
g_min=min(g01, g11);
l_max=max(l0, l1);
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%end;
%else %if &dose=1 %then %do;
g01=p1*((1-err/p1)*(1-pow2)*pow2*&r3+(1-err/p1)*pow2*&r2+err/p1*&r2)
/&r2+(1-p1)*&&g1_&pdose;
g02=&&g1_&pdose;
g11=p2*((1-power2/p2)*(1-pow2)*pow2*&r3+(1-power2/p2)*pow2*&r2
+&power2/p2*&r1)/&r1+(1-p2)*&&g1_&pdose*&r2/&r1;
g12=((1-pow2)**2*pow2*&r3+(1-pow2)*pow2*&r2+pow2*&r1)/&r1;
g03=(err*&r2+(1-err)*pow2*&r2+(1-err)*(1-pow2)*pow2*&r3)/&r2;
l0=g02-g01;
l1=g12-g11;
g_min=min(g01, g11);
l_max=max(l0, l1);
%end;
run;
data report;
set report tmp2;
run;
%end;
%end;
data report;
set report;
if _n_=1 then delete;
run;
proc sort data=report out=sorted;
by l_max;
run;
proc print data=report noobs;
var dose di p1 p2 g11 g01 g03 g12 l_max;
run;
** pick the design with minimum maximum opportunity loss **;
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data _null_;
set sorted(obs=1);
call symput("pcut&dose", trim(left(put(p1, 6.5))));
call symput("g0_&dose", trim(left(put(g01, 6.5))));
call symput("g1_&dose", trim(left(put(g11, 6.5))));
run;
data design;
set design sorted(obs=1);
run;
%end;
title "P=&p Pa=&pa Sample sizes=&ni1 &nni weights=&r3 &r2 &r1";
proc print data=design noobs;
where dose>.;
var dose di p1 p2 g11 g01 g03 l_max;
run;
%mend;
%dsn(p=0.1, pa=0.14, ni1=200, n01=200, nn0=1000, nni=1000, msz=200000,
r3=1, r2=2, r1=3);
%dsn(p=0.1, pa=0.14, ni1=200, n01=200, nn0=1000, nni=1000, msz=200000,
r3=1, r2=3, r1=5);
%dsn(p=0.1, pa=0.14, ni1=200, n01=200, nn0=1000, nni=1000, msz=200000,
r3=1, r2=3, r1=7);
%dsn(p=0.1, pa=0.14, ni1=200, n01=200, nn0=1000, nni=1000, msz=200000,
r3=1, r2=4, r1=9);
%dsn(p=0.1, pa=0.14, ni1=300, n01=300, nn0=1000, nni=1000, msz=200000,
r3=1, r2=2, r1=3);
%dsn(p=0.1, pa=0.14, ni1=300, n01=300, nn0=1000, nni=1000, msz=200000,
r3=1, r2=3, r1=5);
%dsn(p=0.1, pa=0.14, ni1=300, n01=300, nn0=1000, nni=1000, msz=200000,
r3=1, r2=3, r1=7);
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%dsn(p=0.1, pa=0.14, ni1=300, n01=300, nn0=1000, nni=1000, msz=200000,
r3=1, r2=4, r1=9);
%dsn(p=0.1, pa=0.14, ni1=400, n01=400, nn0=1000, nni=1000, msz=200000,
r3=1, r2=2, r1=3);
%dsn(p=0.1, pa=0.14, ni1=400, n01=400, nn0=1000, nni=1000, msz=200000,
r3=1, r2=3, r1=5);
%dsn(p=0.1, pa=0.14, ni1=400, n01=400, nn0=1000, nni=1000, msz=200000,
r3=1, r2=3, r1=7);
%dsn(p=0.1, pa=0.14, ni1=400, n01=400, nn0=1000, nni=1000, msz=200000,
r3=1, r2=4, r1=9);
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APPENDIX D
SAS PROGRAMS USED TO OBTAIN THE OPTIMAL CUT POINTS
WHEN STEPDOWN TESTING APPROACHED IS USED
options symbolgen mprint mlogic;
%macro dsn(p=, pa=, ni1=, n01=, nni=, nn0=, msz=, r3=, r2=, r1=, seed=1009);
data design;
dose=.; di=.; p1=.; p2=.; pct_med=.; err95=.; power95=.; g11=.; g01=.;
g03=.; l1=.; g01=.; g02=.; l0=.; l_max=.; g_min=.;
run;
%do i=1 %to 2;
data report;
dose=.; di=.; p1=.; p2=.; pct_med=.; err95=.; power95=.; g11=.; g01=.;
g03=.; l1=.; g01=.; g02=.; l0=.; l_max=.; g_min=.;
run;
%let dose=%eval(3-&i);
%let pdose=%eval(3-&i+1);
%let ni=%sysevalf((&nni-&ni1)*(&dose-1)/(3-&dose+1)+&nni);
%let n0=%sysevalf((&nn0-&n01)*(&dose-1)/(3-&dose+1)+&nn0);
%let ni2=%sysevalf((&nni-&ni1)*(&dose)/(3-&dose)+&nni);
%let n02=%sysevalf((&nn0-&n01)*(&dose)/(3-&dose)+&nn0);
data rn1 rn2 rn3;
do i=1 to &msz;
m=ranbin(&seed,&n01,&p);
z1=rannor(&seed);
z2=rannor(&seed);
output rn1;
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end;
do i=1 to &msz;
m02=ranbin(&seed,&n0.-&n01,&p);
mi2=ranbin(&seed,&ni.-&ni1,&p);
m01=ranbin(&seed,&n01,&p) ;
mi1=ranbin(&seed,&ni1,&p);
output rn2;
end;
do i=1 to &msz;
m01=ranbin(&seed,&n01,&p);
mi1=ranbin(&seed,&ni1,&pa);
m02=ranbin(&seed,&n0.-&n01,&p);
mi2=ranbin(&seed,&ni.-&ni1,&pa);
output rn3;
end;
run;
data _null_;
mu=log(&pa/(1-&pa)/(&p/(1-&p)));
s1=sqrt(1/(&p*&n01)+1/(&n01-&p*&n01)+1/(&p*&ni1)+1/(&ni1-&p*&ni1));
s2=sqrt(1/(&p*&n0)+1/(&n0-&p*&n0)+1/(&p*&ni)+1/(&ni-&p*&ni));
s3=sqrt(1/(&p*&n02)+1/(&n02-&p*&n02)+1/(&p*&ni2)+1/(&ni2-&p*&ni2));
rho=(s2*s2)/(s1*s2);
call symput("s1", trim(left(put(s1,10.6))));
call symput("s2", trim(left(put(s2,10.6))));
call symput("s3", trim(left(put(s3,10.6))));
call symput("rho", trim(left(put(rho,10.6))));
call symput("mu", trim(left(put(mu,10.6))));
run;
%do di=-50 %to 50;
%let va=0;
data _null_;
p1=0;
p2=0;
min=max(0, &di);
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max=min(&ni1, &n01+&di);
if max<&ni1 then do;
p1=p1+(1-probbnml(&p, &ni1,max));
p2=p2+(1-probbnml(&pa,&ni1,max));
end;
do n=min to max;
if n>0 then do;
p1=p1+(probbnml(&p,&ni1,n)-probbnml(&p,&ni1,n-1))
*probbnml(&p,&n01,n-&di);
p2=p2+(probbnml(&pa,&ni1,n)-probbnml(&pa,&ni1,n-1))
*probbnml(&p,&n01,n-&di);
end;
else if n=0 then do;
p1=p1+probbnml(&p,&ni1,n)*probbnml(&p,&n01,n-&di);
p2=p2+probbnml(&pa,&ni1,n)*probbnml(&p,&n01,n-&di);
end;
end;
call symput("p1",trim(left(put(p1,8.7))));
call symput("p2",trim(left(put(p2,8.7))));
if p1>0.05 and p1<0.99 then do;
call symput("va","1");
call symput("p95",trim(left(put((1-0.05/p1)*100,8.7))));
end;
run;
%if %substr(&va,1,1)=1 %then %do;
data tmp2;
set rn1;
if m+&di>0 then do;
n=m+&di-.5;
lambda=((n+0.5)/(&ni1-n+0.5)) / ((m+.5)/(&n01-m+.5));
end;
else if m+&di<=0 then lambda=0.00000001;
zi1=z1*&s1;
if zi1>=log(lambda) then do;
zi=&rho*&s2*z1+sqrt(1-&rho*&rho)*&s2*z2;
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output;
end;
run;
proc univariate data=tmp2 noprint;
var zi;
output out=out pctlpts=&p95 pctlpre=pct_ pctlname=med;
run;
data _null_;
set out;
call symput("pct_med", trim(left(put(pct_med,10.6))));
run;
data _null_;
set rn2 end=last;
retain err95;
if _n_=1 then err95=0;
if mi1-m01>=&di then do;
m0=m01+m02;
mi=mi1+mi2;
odds=((mi+0.5)/(&ni-mi+0.5))/((m0+0.5)/(&n0-m0+0.5));
z=log(odds);
if z>&pct_med then err95=err95+1;
end;
if last then call symput("err95", trim(left(put(err95/&msz,10.6))));
run;
data _null;
set rn3 end=last;
retain power95;
if _n_=1 then power95=0;
if mi1-m01>=&di then do;
m0=m01+m02;
mi=mi1+mi2;
odds=((mi+0.5)/(&ni-mi+0.5))/((m0+0.5)/(&n0-m0+0.5));
z=log(odds);
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if z>&pct_med then power95=power95+1;
end;
if last then call symput("power95", trim(left(put(power95/&msz,10.6))));
run;
/***********************************************************************
g01: gain when current dose not effective and use adaptive
g02: gain when current dose not effective and only enroll first stage
g03: gain when current dose not effective and enroll all subjects
g11: gain when current dose effective and use adaptive
g12: gain when current dose effective and enroll all subjects
************************************************************************/
data tmp2;
dose=&dose;
p1=&p1;
p2=&p2;
di=&di;
err95=&err95;
pct_med=&pct_med;
power95=&power95;
pow2=probnorm((&mu-probit(0.95)*&s2)/&s2);
pow3=probnorm((&mu-probit(0.95)*&s3)/&s3);
%if &dose=2 %then %do;
g01=pow2*&p1+pow3*(1-&p1);
g11=(p2*pow2*(1-&power95/p2)*&r3+p2*pow2*(&power95/p2)*&r2+(1-&p2)
*pow3*&r3)/&r2;
g02=pow3;
g12=(pow2*(1-pow2)*&r3+pow2**2*&r2)/&r2;
g03=pow2;
l0=g02-g01;
l1=g12-g11;
g_min=min(g01, g11);
l_max=max(l0, l1);
%end;
%else %if &dose=1 %then %do;
g01=p1*(pow2*(1-pow2)*&r3+pow2**2*&r2)/&r2+(1-p1)*&&g1_&pdose;
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g02=&&g1_&pdose;
g03=(pow2*(1-pow2)*&r3+pow2**2*&r2)/&r2;
g11=p2*(pow2*(1-pow2)*&r3+pow2**2*(1-power95/p2)*&r2+pow2**2
*&power95/p2*&r1)/&r1+(1-p2)*&&g1_&pdose*&r2/&r1;
g12=(pow2*(1-pow2)*&r3+pow2**2*(1-pow2)*&r2+pow2**3*&r1)/&r1;
l0=g02-g01;
l1=g12-g11;
g_min=min(g01, g11);
l_max=max(l0, l1);
%end;
run;
data report;
set report tmp2;
run;
%end;
%end;
data report;
set report;
if _n_=1 then delete;
run;
proc sort data=report out=sorted;
by l_max;
run;
proc print data=report noobs;
var dose di p1 p2 g11 g01 g12 g03 l_max;
run;
data _null_;
set sorted(obs=1);
call symput("pcut&dose", trim(left(put(p1, 6.5))));
call symput("g0_&dose", trim(left(put(g01, 6.5))));
call symput("g1_&dose", trim(left(put(g11, 6.5))));
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call symput("g2_&dose", trim(left(put(g03, 6.5))));
run;
title "P=&p Pa=&pa sample sizes=&ni1 &nni weights=&r3 &r2 &r1";
data design;
set design sorted(obs=1);
run;
%end;
proc print data=design noobs;
where dose>.;
var dose di p1 p2 g11 g01 g03 l_max;
run;
%mend;
%dsn(p=0.1, pa=0.14, ni1=200, n01=200, nn0=1000, nni=1000, msz=400000,
r3=1, r2=2, r1=3);
%dsn(p=0.1, pa=0.14, ni1=200, n01=200, nn0=1000, nni=1000, msz=400000,
r3=1, r2=3, r1=5);
%dsn(p=0.1, pa=0.14, ni1=200, n01=200, nn0=1000, nni=1000, msz=400000,
r3=1, r2=3, r1=7);
%dsn(p=0.1, pa=0.14, ni1=200, n01=200, nn0=1000, nni=1000, msz=400000,
r3=1, r2=4, r1=9);
%dsn(p=0.1, pa=0.14, ni1=300, n01=300, nn0=1000, nni=1000, msz=400000,
r3=1, r2=2, r1=3);
%dsn(p=0.1, pa=0.14, ni1=300, n01=300, nn0=1000, nni=1000, msz=400000,
r3=1, r2=3, r1=5);
%dsn(p=0.1, pa=0.14, ni1=300, n01=300, nn0=1000, nni=1000, msz=400000,
r3=1, r2=3, r1=7);
%dsn(p=0.1, pa=0.14, ni1=300, n01=300, nn0=1000, nni=1000, msz=400000,
r3=1, r2=4, r1=9);
%dsn(p=0.1, pa=0.14, ni1=400, n01=400, nn0=1000, nni=1000, msz=400000,
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r3=1, r2=2, r1=3);
%dsn(p=0.1, pa=0.14, ni1=400, n01=400, nn0=1000, nni=1000, msz=400000,
r3=1, r2=3, r1=5);
%dsn(p=0.1, pa=0.14, ni1=400, n01=400, nn0=1000, nni=1000, msz=400000,
r3=1, r2=3, r1=7);
%dsn(p=0.1, pa=0.14, ni1=400, n01=400, nn0=1000, nni=1000, msz=400000,
r3=1, r2=4, r1=9);
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